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1 Introduction 
1.1 General introduction 
Many drugs, especially peptides and proteins require parenteral delivery for bypassing the 
hepatic first-pass effect and avoiding enzymatic degradation in the gastrointestinal tract. 
Therefore, injections in the form of sterile solutions, emulsions or suspensions are indicated. 
Among these formulations, injected suspensions can be efficient depot formulations with 
prolonged drug release compared to solutions [1]. They provide advantages to deliver higher 
doses and insoluble or poorly soluble pharmaceutical ingredients can be administered. 
Resistance to degradation, including hydrolysis, oxidations or microbial activity is further 
improved by using the solid drug form [2]. The subcutaneous or intramuscular administration 
route offers benefits as it enables self-application of the drug, resulting in lower medical costs 
and better compliance of the patients. However, only small volumes up to 1.5 mL may be 
injected [3] and therefore either high concentrations or a high potency of the active ingredient 
are required. Highly concentrated formulations for subcutaneous administration are frequently 
suspensions due to the limited solubility of many drugs. A sufficiently low viscosity of these 
suspensions is pivotal to allow a subcutaneous injection via 25 to 27 Gauge needles [4]. 
Moreover, the needle size creates limitations for the drug particle size in order to avoid needle 
clogging. One drawback, however, is that subcutaneously applied suspensions may produce 
irritations, indurations, sloughing or abscess formation, which can be painful to the patients [5]. 
In addition, the injection site must be changed if regular injections are required [5]. 
 
A subcutaneously applied suspension is the drug formulation of choice for Cilengitide 
(EMD 121974), an antineoplastic therapeuticum. Cilengitide is a cyclized pentapeptide 
consisting of the amino acid sequence L-Arg-Gly-L-Asp-D-Phe-N(Me)-L-Val [6]. Several 
polymorphs are known, whereby the polymorph A1 is most stable and least water-soluble and 
therefore most suitable for a suspension formulation [7]. The RGD-sequence (L-Arg-Gly-L-
Asp) of the peptide binds to the integrin receptors αvβ3 and αvβ5 and leads to the inhibition of 
angiogenesis and apoptosis. Intended indications have been glioblastoma [8], prostate cancer 
[9], non small cell lung cancer [10] or recurrent and/or metastatic squamous cell carcinoma of 
the head and neck [11]. 
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1.2 Suspensions 
1.2.1 Classification of suspensions 
Suspensions can be generally classified according to various criteria. Coarse suspensions 
contain dispersed particles larger than 1 µm, while particles are smaller than 1 µm in colloidal 
suspensions [12]. Regarding the intended route of delivery, pharmaceutical suspensions are 
broadly divided into three general classes [13]: orally administered (sometimes referred to as 
mixtures), externally applied (topical lotions) and injectable (parenteral) suspensions. The solid 
content varies, depending on the use of the suspension, between 0.5 % and 40 %. Diluted 
suspensions with a solid concentration between 0.5 and 5 % are used for parenteral 
application, except for insoluble forms of penicillin with antibiotic concentration exceeding 30 % 
[14]. Further well-known parenteral crystal suspensions contain NPH-insulin (neutral 
protamine hagedorn or isophane insulin) or a corticoid (Volon®, Diprosone® Depot) with 
concentration up to 40 mg/mL (Volon®). They are efficient depot formulations. 
Taking the electrokinetic nature of solid particles into consideration, suspensions may be 
classified as flocculated or deflocculated systems. Deflocculated suspensions are 
characterized by separated, uniformly dispersed particles which settle slowly whereas the 
supernatant remains cloudy. The sediment can be closely packed (“cake”) and can be difficult 
to redisperse [2]. In flocculated suspensions, particles form loose aggregates which settle 
rapidly. The sediment is easy to redisperse due to its scaffold-like structure [2]. A continuous 
rigid three-dimensional particulate network structure is built at quiescent conditions when the 
volume fraction is above the percolation threshold or most recently named the gel point ϕg [15]. 
The appearance is somewhat unsightly due to the rapid sedimentation and the presence of an 
obvious, clear supernatant. This can be optimized by increasing the volume of the sediment. 
Flocculated formulations are the most common type of parenteral suspension [2]. They have 
less potential to cause physical stability problems, above all caking [2]. 
 
1.2.2 Interaction between particles in suspension 
The aggregation potential of dispersions is defined by attractive and repulsive forces which 
exist between the suspended particles [16]. The result of particle interaction is explained by 
the DLVO theory, which in fact applies for colloidal dispersion, but is also valid for coarse 
suspension systems as confirmed by Kayes [17]. 
The potential energy of interaction, VT is the result of repulsion VR and attraction VA [Eq. 1]: 
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𝑉𝑇 =  𝑉𝑅 +  𝑉𝐴 [Eq. 1] 
 
The repulsive potential VR is influenced by the zeta potential, the particle radius, the 
interparticular distance and the dielectric constant of the medium. The attractive potential VA 
depends mainly on the particle radius and the interparticular distance [16, 18]. Figure 1 shows 
the interaction energy as a function of the distance between two particles [16]. 
 
  
Figure 1: Schematic representation of the variation of potential energy with distance according to the 
Derjaguin-Landay-Verwey-Overbeek (DLVO) theory pursuant to [19]. 
 
If a particle approaches another particle, it will enter a radius of long-range forces of attraction, 
the secondary minimum. At this minimum, flocculated suspensions are formed which are easy 
to resuspend. However, the secondary minimum does not occur in all cases [20] as it depends 
on specific conditions (e.g. certain electrolyte concentrations) [18]. Further reduction in the 
distance leads to increased repulsive forces, which stabilize suspensions in the deflocculated 
state [16]. If these repulsive forces are overcome by particles with high kinetic energy, these 
particles will enter the primary minimum, a state characterized by dense particle packing and 
strong attractive forces. A hard cake will be formed which is very difficult to redisperse [16]. 
Stable dispersions can be obtained by electrostatic stabilization or by steric stabilization due 
to adsorption of a non-ionic polymer, e.g. gum or cellulosic or surfactant, e.g. polysorbate 80 
[1, 12, 16, 18] which both affect the repulsive potential VR [18] and thus, the potential energy 
of interaction VT. The steric stabilization is relatively insensitive to the presence of electrolytes 
in the aqueous vehicle [1]. 
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1.2.3 Physical stability of a suspension 
Sedimentation and floating 
Formulation development of suspensions is very complex and challenging from a 
physicochemical point of view due to the coexistence of a solid (internal) and a liquid (external) 
phase prone to physical instabilities [16]. In addition to caking, sedimentation and flotation are 
further phenomena of suspension instability which compromise dosing uniformity. 
Sedimentation or flotation occur as soon as differences in density exist between the solid and 
liquid phase [16]. The settling kinetics of diluted dispersions with spherical, monodispersed 
particles can be described by the Stokes´ equations [20]: 
ν = 
2𝑟2(𝜌𝑆 − 𝜌𝐿)𝑔
9ƞ
 [Eq. 2] 
The velocity (ν) of sedimentation (or flotation) at specific differences in density (ρS - ρL) between 
the solid (ρS) and liquid (ρL) phase depends on the radius r of the dispersed particles and on 
the viscosity of the liquid phase ƞ. At a given density difference, a lower rate of sedimentation 
can be achieved by particle size reduction or an increase in the viscosity of the medium, 
respectively. Common viscosity enhancers used in parenteral suspensions are cellulose 
derivates, gelatin or polyvinyl pyrrolidone. Floating can be prevented by wetting agents such 
as surfactants [16]. 
However, Stokes´ law is invalid for suspensions containing more than 2 % of solids as the 
higher solid content imparts additionally viscosity to the system and particle-particle 
interactions increase [16]. Furthermore, Stokes´ law does not account for the dielectric 
constant, which has an influence on the zeta potential and thus, on the settling rate as well as 
Brownian movement which counteracts sedimentation to a measurable extent [16]. 
 
Particle size stability 
Crystal growth, also known as Ostwald ripening, is another phenomenon of physical instability 
of suspensions. The solubility of a compound is constant for larger particles and depends on 
the compound, the dispersion medium and the temperature. Smaller particles exhibit higher 
surface free energy and are therefore more soluble in the dispersion medium. This effect is 
described by the Ostwald-Freundlich equation [21] 
𝜌𝜐
𝑅𝑇
𝑀
ln
𝑆𝑟
𝑆∞
=
2 𝛾𝑠𝑙
𝑟
 [Eq. 3] 
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where Sr is the solubility of particles of radius r, S∞ the normal solubility value, γsl is the 
interfacial tension, and υ represents the number of moles of ions formed from one mole of 
electrolyte and ρ the density of the solid. M is the molecular weight, R the gas constant and T 
the absolute temperature. A drug concentration gradient between the small and large particles 
is created, leading to molecule diffusion from the higher concentration surrounding small 
particles to areas around larger particles with lower drug concentration. The drug crystallizes 
onto the large particles as supersaturation is generated. The diffusion process creates an 
unsaturated solution around the small particles causing further dissolution of the molecules 
from the small particles into the bulk medium. As a consequence, the smaller particles dissolve 
over time while larger particles will grow in size, leading to a shift in particle size distribution of 
the suspension. Factors that promote crystal growth are a wide particle size distribution, 
changes in pH and temperature, dissolution and recrystallization processes as well as 
polymorphism and solvate formation [1, 2]. Using a narrow particle size distribution, the least 
soluble polymorph and solvate form and choosing appropriate storage conditions [1, 2], the 
risk can be minimized. Viscosity enhancing agents may prevent Ostwald ripening as the 
mobility of the suspended particles in the coherent phase decreases. Certain hydrophilic gums 
[1, 2] or surfactants [1, 16] may adsorb at the particle surface and retard crystal growth due to 
a film barrier or dissipating the free surface energy of particles by reducing the interfacial 
tension, respectively. However, the tolerable viscosity of subcutaneous formulations is limited 
due to requirements with regard to syringeability and injectability, limiting the use of viscosity 
enhancers. Syringeability is defined as the ability of a parenteral solution or suspension to pass 
easily through a hypodermic needle during the transfer of the product from a vial to a 
hypodermic syringe prior to injection [22]. Injectability refers to the subsequent ejection of the 
formulation into the desirable site of administration [22]. Increased viscosity of suspensions 
hinders syringeability as well as injectability [1, 2] and further promotes syringe clogging [2]. 
 
1.2.4 Rheological properties 
Diluted suspensions as commonly used for the parenteral route contain 0.5 - 5 % of the API 
[14] and behave like low-viscous, Newtonian systems. However, concentrated suspensions 
typically follow non-Newtonian flow [16], where viscosity changes with applied shear rate. They 
show a maximum viscosity at rest caused by high interparticular interaction [16]. The viscosity 
decreases considerably when the yield point is overcome by applying a minimum force. 
Beyond that point, viscosity either remains constant for Bingham plastic systems (plastic flow) 
or further decreases with increasing shear rate (pseudoplastic flow / shear thinning) [16, 19]. 
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Pseudoplastic flow is beneficial for parenteral suspensions as the reduced viscosity of the 
sheared system facilitates syringeability and injectability [16]. 
 
In pharmaceutical literature, viscosity reduction of suspensions is rarely discussed as viscosity 
enhancement is more often required to stabilize the formulation. Highly concentrated protein 
solutions such as monoclonal antibodies which have gained interest recently, often suffer from 
high viscosities, leading to some reports discussing the viscosity of parenteral solutions [23]. 
Viscosity reduction of suspensions is more often requested in the field of process technology. 
Coal-water mixtures exhibit high viscosities, so that they are difficult to pump [24]. The 
knowledge of the rheological properties of bentonite clays is of great importance as they are 
used as thickening agents in many industrial preparations such as drilling fluids, cement and 
paint [25]. Another field that requires viscosity reduction is the process of ceramics fabrication, 
where polymer dispersants are generally added in order to control aggregation properties and 
obtain highly concentrated suspensions [26]. 
Viscosity is strongly influenced by the nature and magnitude of the interparticular forces [23, 
24, 27, 28] as well as the interactions of the suspended particles with the solvent and co-
solutes [23]. Generally, three different forces can be distinguished in suspensions [28]. 
Hydrodynamic forces, which are existent in all flowing suspensions, result from the relative 
motion of particles to the surrounding fluid and particles. Brownian force, noticeable for 
systems containing submicron particles (< 1 µm), is a fluctuating force which is the 
consequence of particle collisions with molecules of the fluid. Colloidal forces in immobile 
suspensions can be attractive or repulsive. Van der Waals, electrostatic attractive and 
hydrophobic interactions, bridging and depletion are attractive forces. Repulsive forces include 
electrostatic repulsion, steric hindrance, hydration and structural forces [28]. The sum of all 
effects determines the particular interaction, as already mentioned discussing the DLVO 
theory, and can be influenced by the nature of solids, the properties of the dispersion medium 
and the addition of excipients. 
The probability of solute or particle interaction increases with concentration as the spatial 
distances between the particles or dissolved molecules are reduced [23, 29]. Hence, short-
range interactions such as van der Waals forces, dipole-dipole and hydrophobic interactions, 
hydrogen bonding and specific ionic attractions [30] can play a significant role in concentrated 
compositions [23, 31]. Important physical parameters influencing the interaction and thus, the 
viscosity of the preparation are the dispersed phase content ϕ, the particle shape, size and 
size distribution, the nature of the dispersion medium and the temperature. The dispersed 
phase content is defined as the ratio in volume (weight) of the dispersed phase to the total 
volume (weight) of the dispersion and has the greatest impact on viscosity [32, 33]. The 
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viscosity increases with increasing phase content as described by the Einstein equation ([Eq. 
4]) for very diluted suspensions (ϕ < 0.01) of hard, noninteracting spheres [19]. 
ƞ𝑆 = ƞ0(1 + 2.5 𝜙) [Eq. 4] 
 
In more concentrated suspensions, aggregates are formed due to more interparticular 
attractions and the dispersion medium is trapped within the aggregates [16], increasing the 
effective volume of the solid phase ϕe of the flocculated system and thus, the viscosity [Eq. 5] 
including a as the two-body interaction parameter between the particles, is more accurate [32]: 
ƞ𝑆 = ƞ0(1 + 2.5 𝜙𝑒  +  𝑎 𝜙𝑒
2) [Eq. 5] 
 
The semiempirical Thomas equation describes the viscosity of suspensions for ϕ values up to 
0.6 [Eq. 6]. 
ƞ𝑆 = ƞ0(1 + 2.5𝜙𝑒  +  10.05 𝜙𝑒
2  +  0.00273 𝑒16.6 𝜙𝑒) [Eq. 6] 
 
The last term becomes more important as ϕ increases and the viscosity increases 
exponentially [32]. 
Another way to calculate the viscosity of concentrated suspensions is the Krieger-Dougherty 
equation [Eq. 7] with the intrinsic viscosity [ƞ0] and the maximum packing fraction ϕm, which 
describes the maximum volume that particles occupy without deformation [34]. 
ƞ𝑆 = ƞ0  (1 −  
𝜙
𝜙𝑚
)
−𝜙𝑚 [ƞ]
 [Eq. 7] 
 
For monodisperse particles, ϕm is between 0.6 and 0.64 approximately [32]. 
When a colloidal solid particle is partly soluble in the medium, solvation layers are built and 
lead to an apparent swelling of the particle which increases ϕ and hence the viscosity [16]. [Eq. 
8] includes this effect. 
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ƞ𝑆 = ƞ0[1 + 2.5(1 + 
𝑡𝑖
𝑅
)3ϕ] =  ƞ0[1 + 2.5 (1 +
ti ∗ ρAsp
3
)
3
ϕ] [Eq. 8] 
 
ti is the thickness of the solvation layer, ρ is the density of the dispersed phase and Asp is the 
specific surface area of the solid particles, assuming spherical. All of the mentioned equations 
do not consider either particle size, shape or size distribution. Also, the non-Newtonian 
behavior of systems with ϕ values above 0.2 [32] is not considered. 
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1.2.5 Parameter influencing the viscosity 
The effect of the particle size on the viscosity of concentrated suspensions is important and 
depends on the counterbalance of hydrodynamic and Brownian forces [16, 32]. Considering 
repulsive particle systems, the relative importance of electrostatic repulsive forces increases 
as the diameter is decreased as Boersma et al have shown [35]. Thereby, the effective volume 
fraction of smaller particles due to the larger double layer is increased and the mean distance 
between the particles is shorter for smaller particles, resulting in an extended double layer 
interaction [28]. Consequently, viscosity is increased, especially at low shear rates. Shi et al. 
[33] showed that slurries exhibited two different types of flow curves in dependence of particle 
size and total concentrations. Dilatant flow was observed for slurries with low solid 
concentration (15 %), where the viscosity increased with increasing fines content in addition 
to the development of a yield stress. At intermediate solids concentrations and coarse particle 
size (20 % < 38 µm) classic Bingham plastic flow occurred. The slurries behaved like 
pseudoplastics at the highest solid concentration (45 %) and higher fines content (> 20 %). In 
general, yield stress appeared by increasing the slurry concentration or fines content and the 
flow behavior changed from dilatant over plastic to pseudoplastic when the solid content was 
increased. 
Flocculated systems also show higher viscosities as the density of inter-particle contacts is 
increased and the microstructure of the suspension affected [28]. 
 
In general, a wider particle size distribution leads to lower viscosity [32, 36], mainly at higher 
shear rates [28] as confirmed by [37, 38] due to an enhancement of packing efficiency [28]. 
Chang et. al found that a bimodal size distribution reduces the viscosity of polystyrene spheres 
[39] which was further confirmed by other authors [40, 41]. However, the amount of very fine 
particles remains important. The very fine particles and the continuous phase build a 
pseudocontinuous phase, decreasing the effective volume fraction. A further increase raises 
the viscosity due to colloidal interactions overcoming the effect of volume fraction reduction 
[28, 32]. 
 
Regarding the particle shape, suspensions with more irregularly shaped particles are more 
viscous compared to suspensions containing spherical particles [28, 32, 42, 43], confirmed by 
the study of Graham et al. [44] and Zhang et al. [45]. As particle shape deviates from sphericity, 
the maximum packing fraction ϕm decreases and thus, viscosity increases, according to the 
Krieger-Dougherty equation ([Eq. 7]). Additionally, [ƞ] is higher for unsymmetrical particles than 
for spherical and cubic particles due to an increasing disruption of the flow field, additionally 
contributing to the viscosity increase [28]. Non-spherical particle suspensions may exhibit 
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shear-thickening or shear-thinning flow behavior [32]. Shear-thickening occurs when particles 
interact more with each other under shearing as typically observed for glass rods, and is 
caused by shear-induced microstructural changes [28]. Shear-thinning is typical for fibers 
suspensions, where fibers align in the direction of shear at higher shear rates, minimizing their 
interactions [32]. 
 
A decrease in viscosity is generally observed with higher temperatures [32] as interfacial 
properties and the volume expansion of the phases are modified. The liquid medium expands 
more than the solid phase, leading to a lower solid content and a decrease in viscosity at higher 
temperature. Additionally, the viscosity of the continuous phase is reduced. Colloidal systems 
also exhibit higher Brownian dispersion force with increased temperature. However, if 
flocculation is induced, viscosity increases due to the increased effective volume fraction ϕe of 
the flocculated systems [46]. 
 
The interparticle forces can be chemically modified by varying the pH [3, 24, 25], the addition 
of electrolytes [47], surface-active agents [48-50] or polymers [26, 51]. The variation in pH 
influences the electrostatic force, whereby the van der Waals forces remain constant for a 
given system. At a pH near the isoelectric point, systems show the highest viscosity. As 
charge-charge repulsion is minimal between neutral molecules, attractive forces dominate at 
the isoelectric point, resulting in a flocculated system. This pH-effect was observed by Liu et 
al. [3] and Chari et al. [52] in antibody solutions. Desai et al. [48] demonstrated this pH 
dependence of the viscosity for a pyrophyllite - water slurry. 
 
The addition of electrolytes influences the double layer thickness and the zeta potential of the 
suspended particles, affecting the electric double layer repulsive forces [28] and hence the 
rheological properties. Two different effects could be observed with increasing electrolyte 
concentrations [28]. The effective volume fraction of the solid phase is reduced due to the 
compressed double layer [28, 29]. Furthermore, the range and magnitude of the electrostatic 
repulsive force is decreased [28]. Low concentrations lead to a compressed double layer and 
reduced, but still repulsive forces, resulting in lower viscosities. Due to the limitation of the 
double layer compression, only the repulsive forces are reduced at high concentrations and 
cannot balance the attractive forces. Aggregates are built in the secondary minimum [29], and 
consequently, the viscosity increases [28]. 
This concept was confirmed by Zhou et. al [53] observing the effect of electrolytes on metal 
oxide suspensions and Heller et. al [54] analyzing montmorillonite suspensions. Chari et. al 
[52] and Liu et. al [3] found a viscosity reduction of antibody solutions with the addition of salt. 
Introduction 
11 
Zaman et. al [55] showed that bidisperse silica suspensions are more fluid with increased salt 
concentration. When increasing salt concentrations were added to a bentonite suspension, the 
viscosity decreased due to the above mentioned effects, leading to a change of flow properties 
from shear-thinning behavior to Newtonian and shear thickening [56]. 
 
Dispersants added to the suspension may exert a multitude effects influencing the rheology 
and the stability of the formulation [26]. Surfactants absorbing to the surface of suspended 
particles may sterically or electrosterically stabilize the suspension or induce flocculation by 
bridging [26, 49]. Bridging flocculation occurs when a long (usually polymeric) surfactant 
molecule adsorbs onto two separated particles, holding them together [57]. This is mostly 
observed, when the particle surface is covered with a long chain polymer at low concentrations 
[57, 58]. This mechanism was identified by Heath and Tadros [59], investigating the effect of 
polyvinylalcohol on a sodium-montmorillonite suspension. They observed a maximum viscosity 
at an adsorption value corresponding to a quarter of full coverage, where the system is most 
flocculated due to polymer bridges. Further polymer addition reduced the flocculation and 
hence viscosity. Kamibayashi et al. found a drastic viscosity increase of a silica suspension by 
the addition of a polymer inducing flocculation [60]. Depletion flocculation occurs if the 
dispersant do not adsorb onto the particles and the interparticular distance is less than the 
length of the molecules, the molecules are excluded from the gap due to an osmotic pressure 
gradient between the particles and the surrounding solution. An effective attractive force is 
produced leading particles to come closer and flocculate or phase separate [28]. 
Steric stabilization induced by the addition of a surfactant prevents systems from flocculating 
[61]. For steric stabilization, the surface should be sufficiently covered with surfactant 
molecules for effective particle repulsion [28]. The adsorbed surfactants influence the electrical 
double layer interactions due to changes in the surface charge, displacement of counterions 
and changes in the dielectric constant. Secondary, the van der Waals interactions are 
weakened [61, 62] as the steric hindrance prevents the particle to get close in the range of 
attractive forces. Surfactants are effective in both aqueous and non-aqueous media and at low 
and higher solid concentrations [61] and the electrosteric stabilization is insensitive to the 
presence of electrolytes [63]. However, the steric repulsion is a short-range force and only 
present when the stabilizer layers overlap [29]. Schott et al. [64] observed a decrease in 
viscosity with an increase in polyoxyethylated nonionic detergent concentration. This was 
attributed to the deflocculation of the clay particles by steric separation. A viscosity reduction 
of a coal-water mixture with the nonionic surfactant Triton-X 405 achieved by increasing the 
interparticle repulsion forces was also reported by Aktaş [24]. A comparable short-range 
repulsive force can be obtained by electrosteric effects, involving a combination of steric and 
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electrostatic repulsion due to ionizable groups in surfactants. Desai et al. [48] investigated the 
influence of a cationic, anionic and nonionic surfactant on the viscosity and zeta potential of 
the pyrophyllite-water slurry. In general, the addition of an anionic surfactant reduced the 
viscosity as repulsive forces were increased. At very low anionic surfactant concentrations, 
they found a slight increase of viscosity due to bridging. Higher amounts did not further affect 
the fluidity in accordance with constant zeta potential values. The positively charged surfactant 
adsorbed onto the oppositely charged surface using the polar head group, leading to a 
hydrophobic surface. The clay showed a higher viscosity due to an increased coagulation 
tendency. With further addition of surfactant, bilayers were formed and the surface became 
positively charged, resulting in a viscosity reduction. In presence of the nonionic surfactant the 
formation of an enhanced hydration layer led to an increased viscosity in presence of the 
nonionic surfactant. Tunç et al. [65] investigated the effect of a cationic, anionic and nonionic 
surfactant on the electrokinetic and rheological properties of Na-bentonite and sepiolite 
suspensions. They showed that the used surfactants only altered the viscosity and the 
rheological behavior of the sepiolite suspensions, whereby the bentonite containing systems 
were unaffected. The anionic surfactant bound via hydrophobic interaction on the negatively 
charged surface, leading to increased electrostatic repulsion forces and resulting in a decrease 
in viscosity. The nonionic surfactant lowered the viscosity due to a decrease in flocculation. 
The addition of positively charged surfactant caused an overall viscosity reduction, but 
flocculation was observed at 1 mM surfactant concentration. 
 
In conclusion, a variety of parameters influences the interactions of dispersed particles with 
each other and with the solvent and co-solutes and thus, determines the rheological properties 
of a system. Physical parameters include the phase content, the particle size and particle size 
distribution, the particle shape, the dispersion medium and the temperature, whereby the 
phase content has the biggest impact on the viscosity of a system. Chemical parameters 
include the pH, electrolytes or surface-active agents. 
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1.3 Aim of the thesis 
The thesis aimed to develop a highly concentrated suspension of Cilengitide for subcutaneous 
application. The required solid content of the most stable polymorph A 1 of Cilengitide is 
30 % (w/v) to deliver a target dose of 300 mg in 1 mL. The suspended API is evaluated in 
terms of its physical stability including the particle size and structure, sedimentation behavior 
and resuspendability and with respect to its performance parameter like viscosity, 
syringeabillity and injectability. This high amount of active pharmaceutical ingredient (API) 
suspended in water exhibited very high viscosity and a paste-like structure which is unsuitable 
for parenteral application. Therefore, the effect of particle size, pH, ions and the addition of 
surface active agents is examined to finally enable subcutaneous application via a 25 Gauge 
or even smaller needle. Main aspect of the thesis is the characterization of the rheological 
behavior, but also the surface potential and the potential stabilizing effect of phospholipids and 
other surfactants. The interaction of a phospholipid with the API particles, as well as the 
interactions with dissolved API are investigated in more details. Excipients should be 
acceptable for the parenteral route and if possible, commonly used in marketed products and 
the formulation should be simple for clinical practice. 
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2 Materials 
Cilengitide (polymorph A1) was provided by Merck KGaA, Darmstadt, Germany. An optional 
micronization step was performed at the Gesellschaft für Mikronisierung, GfM, Bremen, 
Germany to obtain a narrow and specified particle size between 0.9 (D(10)) and 26 µm (D(90)). 
1,2-Dimyristoyl-sn-glycero-3-phospho-rac-glycerin (sodium salt) (DMPG / Lipoid PG 14:0 / 
14:0), 1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-glycerol (sodium salt) (DPPG / Lipoid 16:0 / 
16:0), 1,2-Distearoyl-sn-glycero-3-phospho-rac-glycerin) (sodium salt) (DSPG / Lipoid PG 
18:0 / 18:0) as well as N-(Carbonyl-methoxypolyethylene glycol-2000)-1,2-Distearoyl-sn-
glycero-3-phosphoethanolamine (sodium salt) (DSPE-PEG 2000 / Lipoid PE 18:0 / 18:0 – PEG 
2000) were acquired from Lipoid AG, Ludwigshafen, Germany. 1,2-Didecanoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (sodium salt) (DDPG / PG 10:0 / 10:0) and 1,2-Dilauroyl-sn-glycero-
3-phospho-(1'-rac-glycerol) (sodium salt) (DLPG / PG 12:0 / 12:0) were bought from Avanti 
Polar Lipids, Inc., Alabaster, Alabama. 
Tween® 80 (polysorbate 80) and Span® 80 (sorbitan monooleate) were obtained from Croda, 
Nettetal, Germany. 
Sodium chloride, potassium chloride, calcium chloride, hydrochloric acid, sodium hydroxide 
and glucose were purchased from Merck KGaA, Darmstadt, Germany. 
For HPLC analysis acetonitrile, methanol, acetic acid, ammoniac, isopropanol and ammonium 
acetate were provided by Merck KGaA, Darmstadt, Germany. 
For sample preparation, aqua ad injectabilia prepared by distillation was used. 
 
3 Methods 
3.1 Analytical methods 
3.1.1 Characterization of the raw material 
Bulk and tapped density 
For the analysis of the bulk and tapped density the Sotax TD 2 was used (Sotax Corporation, 
Horsham, PA). The test was performed three times with the method 1 of the Ph. Eur. 100.0 g 
of the raw material were weighed into a 250 mL cylinder and the unsettled apparent volume 
V0 was read. The tapped volume was determined after 10, 500 and 1250 taps. The difference 
between V500 and V1250 was less than 2 mL and thus, the V1250 was used for the calculation of 
the tapped density (= Vf). Finally, the Hausner ratio HR = V0 / Vf was calculated by using the 
determined volumes. 
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3.1.2 Flowability 
The flowability was determined according to the Ph. Eur. using the Erweka GT (Erweka, 
Heusenstamm, Germany). The powder was introduced in a funnel with the 15 mm outlet 
nozzle. The flow time of the powder on the special GT balance which determined the weight 
of the falling sample was measured. For the micronized material, the outlet of the powder was 
supported by an agitator (level 1). The analysis was done three times. 
 
3.1.3 Angle of repose 
The angle of repose was determined by using the Erweka GT (Erweka, Heusenstamm, 
Germany). The height of the cone of powder on a fixed base is measured and calculated with 
the equation [Eq. 9]. 
tan 𝛼 =
ℎ𝑒𝑖𝑔ℎ𝑡
0.5 ∗ base
 [Eq. 9] 
 
A triplicate determination was done. 
 
3.1.4 Thermogravimetric analysis 
Thermogravimetric analysis were performed with a DSC 1/TGA (Mettler Toledo, Delaware, 
USA) with a 5 K/min heating rate up to 300 °C, under nitrogen. About 25 mg were weighed in 
an aluminium pan. 
 
3.1.5 Dynamic vapor sorption 
The moisture uptake and desorption at different humidity conditions were measured using 
Dynamic Vapor Sorption (Advantage, Surface Measurement systems Ltd, London, UK). The 
required humidity was generated by mixing dry nitrogen and water saturated nitrogen flows, in 
the corresponding proportions using mass flow controllers. The humidity range chosen was 
from 0 to 98 % r. H. in steps of 10% r. H. at 25 °C. The instrument was run in dm/dt mode to 
decide when equilibrium was reached, with the dm/dt set at 0.002 %/min within 10 min. The 
sample weight was approximately 25 mg. 
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3.2 Characterization of the suspension 
3.2.1 Particle size measurement 
The particle size distributions of the formulations were determined with a Mastersizer 2000 
(Malvern Instruments Ltd, Worcestershire, UK). A saturated API-solution with appropriate 
excipients of the samples was used as dispersion medium. After background alignment with 
the dispersion medium, a representative sample of the homogenized suspension was injected 
into the sample cell. The amount was dependent on the API-concentration of the sample and 
selected to obtain an obscuration of 10 – 15 %. 
 
3.2.2 Microscopy 
Microparticles were visualized with a light microscope (Olympus Bx 60, Olympus GmbH, 
Hamburg, Germany). The API-concentration was limited to 60 mg/mL by transparency, so that 
a dilution step with saturated API-solution was required. 20 µl of diluted suspension were 
dropped onto a microscope slide and covered with a slip to be examined at 50 and 100 fold 
magnification. Digital imaging of microparticles were taken with a ColorView camera 
(Olympus Soft Imaging Solutions GmbH, Münster, Germany). 
 
3.2.3 Stereomicroscopy 
The dissolution of a non-micronized crystal was observed using a stereomicroscope (Stereo 
Discovery V20, Carl Zeiss Microscopy GmbH, Jena, Germany). One large non-micronized 
particle was selected, transferred in a cuvette and suspended in water, 2 mg/mL DMPG, a 
non-saturated (4 mg/mL API) or a saturated API-solution (5 mg/mL API). The particle was 
observed over a period of 16 days maximum without agitation. 
 
3.2.4  Scanning electron microscopy 
The samples were imaged using a Leo Supra 35 (Carl Zeiss Microscopy GmbH, Jena, 
Germany). Acceleration voltage was kept constant at 5.0 kV. The sample was coated with 
Platinum. 
 
3.2.5 Zeta potential 
Measurements of the zeta potential (ζ) were performed with a Zetasizer Nano ZS 
(Malvern Instruments Ltd, Worcestershire, UK). The zeta potential was automatically 
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calculated from the electrophoretic mobility based on the Helmholtz-Smoluchowski 
relationship. The high-concentration cell was used to prevent sedimentation of the particles. 
The Cilengitide concentration was 15 mg/mL. Runs were performed in triplicate using an 
effective voltage of 30 mV. 
 
3.2.6 Streaming potential 
The streaming potential is analyzed by the measurement setup of the Mütek PCD-03 
(BTG Mütek GmbH, Herrsching, Germany), (Figure 2). A piston sinusoidally moves up and 
down with a frequence of 4 Hz and forces the suspension to stream through the gap along the 
container wall. Particles, which interacts with the container wall, are polarized according to the 
distortion of the diffuse double layer in the streaming liquid and an electrical potential – the so 
called streaming potential - is measurable between the electrodes. The obtained values are 
not absolute, because a calibration against a reference of known streaming potential is not 
possible. The measurements dependent on pH were conducted with 20 mL of a 50 mg/mL API 
aqueous suspension (n = 6). The DMPG-concentration was adapted to the formulation 
(0.33 mg/mL). The titration was performed with 0.1 M hydrochloric acid. 
 
 
Figure 2: Measurement cell of the Mütek™ PCD-03 (A) and schematic illustration of the separation principle 
of counterions from adsorbed material (B). 
 
3.2.7 Turbidimetry 
The turbidimetry of DMPG dispersions (n = 3) containing dissolved API (4 mg/mL), and 150 mM 
sodium chloride where indicated, was measured with a turbidimeter (2100 AN, Hach Lange, 
Düsseldorf, Germany). The intensity of the light scattered by a sample under defined 
conditions was compared to the intensity of light scattered by a standard reference suspension 
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(400-600 nm, 90°). Size calibration was performed with four Gelex® secondary turbidity 
standards, covering the ranges of 0-2, 0-20, 0-200 and 200-4000 Nephelometric Turbiditry 
Units (NTU). 
 
3.2.8 Dynamic light scattering 
Dynamic light scattering was used for the structural characterization of phospholipid and 
surfactant mixture dispersions. Size measurements of diluted excipient dispersions 
(0.05 mg/mL DMPG, 2 mg/mL polysorbate 80 / sorbitan monooleate with different ratios) as 
well as dispersions including 4 mg/mL API in solution were carried out with a Zetasizer 
Nano ZS (Malvern Instruments Ltd, Worcestershire, UK). The experiments were performed in 
triplicate. 
 
3.2.9 Cryo-transmission electron microscopy 
Cryo-transmission electron microscopy (Cryo-TEM) was conducted at the Albert-Ludwigs-
University of Freiburg, Department of Pharmaceutical Technology with a Leo 912 OMEGA 
electron microscope equipped with a slow-scan CCD camera system (Proscan HSC 2 camera, 
Oxford Instruments, Abingdon, USA) and operating at 120 kV. A small drop (3 µl) of the 
homogenized sample was placed onto a TEM-grid (400 x 100 mesh). Excess solution was 
removed with a filter paper and the sample was immediately shock-frozen by immersion into 
kryogen (90 K) and fixed in a sample holder for the transfer into the microscope. During the 
transfer the temperature was held below -170 °C. The samples were observed and digitalized 
under low exposure rate. 
 
3.2.10 Nuclear magnetic resonance (NMR) spectroscopy 
For NMR spectroscopy samples were prepared in D2O containing 300 mg/mL Cilengitide and 
2 mg/mL DMPG. The pD was adjusted to 4.6 (pH = 4.2), 5.8 (pH = 5.4) and 7.3 (pH = 6.9) with 
0.1 M HCl. The samples were centrifuged (5 min, 12000 rpm) and the clear solution was 
transferred into a 5 mm NMR tube and equilibrated for 30 min. NMR spectra were measured 
at 700 MHz proton resonance frequency and 298 K measuring temperature on a Bruker 
Avance III 700 spectrometer (Billerica, USA) equipped with a CP-TCI probe. 2 D NOESY-
NMR-spectra (Nuclear Overhauser Effect Spectroscopy) were obtained using the standard 
pulse sequences noesyphprrv (80 ms mixing time). 
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3.2.11 Surface tension 
The surface tension of a saturated API-solution and phospholipid dispersions of different 
concentrations was determined using a Wilhelmy plate tensiometer (Krüss Tensiometer K12, 
Krüss GmbH, Hamburg, Germany). The solutions were equilibrated at 20 °C for 10 min before 
measuring. Every 10 s a measurement step was performed automatically until the standard 
deviation was less than 0.02 for water and 0.1 for the samples (maximum 999 steps). The 
determination was performed in triplicate. 
 
3.2.12 Sedimentation analysis 
The sedimentation behavior was analyzed by imaging at different time points. The API amount 
was varied (15 – 300 mg/mL). Suspensions with 150 mg/mL API (highest possible 
concentration) were analyzed by the TurbiScan (TurbiScan LAb™, Formulaction, L´Union, 
France) for a period of 13 h at 25 °C. In the first 30 min, the sample was scanned every minute, 
followed by measurements every 5 min for 2.5 h and every 15 min for 10 h. 
During storage, suspensions with 300 mg/mL API were characterized by the sedimentation 
degree F = Ve/V0 (Ve: final sediment volume, V0: volume at the beginning; n = 3). Therefore, 
the sediment and the total height were analyzed by using the IrfanView software. 
 
3.2.13 Rheometry 
Rheological properties of suspensions were investigated using a rotational rheometer 
(HAAKE Rheostress 1, Thermo Scientific, Karlsruhe, Germany). The shear stress (τ) of the 
samples was measured as a function of shear rate (ẙ) at a constant temperature (20 °C ± 0.1) 
using different plate geometries (P 20, P 35). The measurements were carried out with 
increasing (forward measurements) and decreasing (backward measurements) shear rates. 
The used shear rates depended on the method and were 50 - 1200 or 0.1 - 1000 1/s. 
Measurements were performed in triplicate. The yield point is calculated by using the Casson 
model with the following equation [Eq. 10]: 
√𝜎 =  √𝜎𝑐 + √𝜂𝑐 ∗ √𝛾 [Eq. 10] 
 
The calculation was performed in triplicate. 
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3.2.14 Resuspendability 
The resuspendability of stored suspensions was investigated by subjecting the vials to a 
defined overhead rotation. In a tablet friabiliator (TA of Erweka, Heusenstamm, Germany), 
vials were attached with clamps and moved with a constant rotation speed of 25 rpm (Figure 
3). The time needed for resuspension until the sediment was completely detached from the 
bottom of the vial was measured (n = 3). 
 
Figure 3: Measurement setup for the analysis of resuspendability. 
 
3.2.15 Syringeability 
Syringeability is defined as the ease of withdrawal of a product through a needle from the 
container. The set criterion was an easy withdrawal without air bubbles with a 25 Gauge needle 
(BD Microlance 3 ™, 25G x 5/8 ´´, 0.5 mm x 16 mm, BD Becton Dickinson GmbH, Heidelberg, 
Germany) and a 1 mL syringe (Terumo Syringe without needle, Terumo Medical Corporation, 
New Jersey, USA). The time required for the withdrawal of 1 mL of the suspension was 
measured (n = 3). 
 
3.2.16 Injectability 
Injectability in general means the injection into the desirable site of administration. In case of 
the formulation development, the force required to eject the suspension through a 25 G needle 
into air was determined using a texture analyzer (XT plus, stable micro system Ltd, Surrey, UK) 
operated at a displacement speed of 5 mm/s and with 0.1 g force sensitivity. The average 
value of three samples was analyzed with the corresponding SMS´ Exponent software and 
used for comparison. 
 
 
Methods 
21 
3.3 Manufacturing process 
3.3.1 Milling of API 
The micronization of Cilengitide was performed at the Gesellschaft für Mikronisierung, GfM, 
Bremen, Germany, using an air jet mill (JM 100, Scheffler Metallverarbeitung, Bremen, 
Germany). Particle size specifications are shown in Table 1. 
D (0.1) [µm] D (0.5) [µm] D (0.9) [µm] 
0.9 - 2 5 - 8 16 - 26 
 
Table 1: Particle size specification for micronization of Cilengitide. 
 
3.3.2 Preparation of suspensions 
Cilengitide suspensions were produced by suspending the adequate amount of API (w/v) in 
water and stirring at room temperature for 4 hours. To observe the effect of stirring on particle 
size as a function of time the samples were stirred at room temperature for up to 48 hours. 
Samples were taken at different time points and analyzed. Suspensions containing a 
phospholipid were prepared by dispersing the required amount of excipient (w/v) in 60 °C hot 
water and subsequent cooling down to room temperature while stirring. The API (w/v) was 
added and the suspensions were stirred for 4 hours with a magnetic stirrer. The isotonicity 
agents were then added. In formulations comprising surfactant mixtures, the adequate 
ratio (w/w) of polysorbate 80 and sorbitan monooleate were first homogenized by mixing with 
a magnetic stirrer before dispersing in water at 60 °C. 
For the evaluation of the effect of higher energy levels the samples were subsequently treated 
for 30 s using the Sonotrode HD 2070 (Bandelin, Berlin, Germany) or using the Ultraturrax 
(T 10 basic ULTRA-TURRAX®, IKA®-Werke GmbH & Co. KG, Staufen, Germany). Short-time 
ball-milling was performed with the impact mill Pulverisette 23 (Fritsch, Idar-Oberstein, 
Germany) using zirconium spheres with a diameter of 1 mm or 5 mm. 4 mL were filled in the 
milling cup and milled for 10 min at 45 Hz. 
 
3.4 Storage stability study 
For the stability studies, 2 mL of the suspensions were filled into siliconized 2 mL vials (Fiolax 
Clear, Schott, Müllheim, Germany), stoppered (S2, Daikyo Seiko Ltd., Tokyo, Japan) and 
crimped under lab atmosphere. Three metal beads with a 1 mm diameter (ISOMETALL 
Handelsgesellschaft, Pleidelsheim, Germany) for resuspension were added in some samples 
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as indicated. Samples were stored at 2 – 8 °C (up to one year), 25 °C / 60 % r.H. (9 weeks) or 
40 °C / 75 % r.H. (4 weeks). 
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4 General properties, solid-state and powder characterization of the 
drug substance 
4.1 Crystallinity and polymorphism 
Many pharmaceutical solids exist in different crystalline modifications (polymorphs) that have 
different arrangements and / or conformations of the molecules in the lattice [66]. Different 
polymorphs can have different chemical and physical properties, e.g. apparent solubility, 
dissolution rate, hygroscopicity, chemical reactivity, resulting in a direct impact on the stability, 
dissolution or bioavailability [7]. A metastable drug substance polymorph can change its 
crystalline structure in response to changes in the environmental conditions, processing or 
over time during storage. Today, many companies have to deal with the occurrence of 
polymorphism which may sometimes only be discovered when the medication is already on 
the market [67] as in the case of the popular blood thinner Coumadin® 
(warfarin sodium 2-propanol solvate) and the blood pressure medication Avalide® in 2010 
leading to market recalls [67]. An extraordinary example with a dramatic effect on commercial 
pharmaceuticals was Norvir® in 1998 [68]. Several lots of capsules failed the dissolution profile 
due to the occurrence of a new polymorph with a greatly reduced solubility [68]. Therefore, it 
is essential to use a stable drug substance polymorph. 
The pharmaceutical ingredient of interest, Cilengitide, is a cyclic pentapeptide consisting of the 
amino acid sequence L-Arg-Gly-L-Asp-D-Phe-N(Me)-L-Val (Figure 4) [69]. It has a molecular 
weight of 589 Da. 
 
 
Figure 4: Structural formula of the pharmaceutical ingredient Cilengitide. 
 
+
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The molecule exists in several polymorphic forms with the solvate S2, the tetrahydrate Ia and 
the anhydrous form A1 being the most stable and relevant ones [70]. Table 2 summarizes the 
physicochemical properties of these three polymorphic forms. 
 
 
 Form A1 Form Ia Form S2 
Modification Ansolvate Tetrahydrate 
Unstoichiometric 
water-ethanol solvate 
Unit cell 
Cell volume 
orthorhombic 
2940 Å3 
orthorhombic 
3396  Å3 
orthorhombic 
3373 Å3 
Density 1.330 g/cm3 1.285 g/cm3 1.319 g/cm3 
Melting / degradation 304 °C (onset) 217 °C (onset) 212 °C (onset) 
Thermogravimetric 
Analysis 
weight loss 
Less than 0.3 wt % up 
to 150 °C 
10.4 wt % up to 140 
°C (step) 
13.2 wt % up to 180 °C 
(step) 
Dynamic vapour 
sorption 
- not hygroscopic acc. 
Ph. Eur. 
- no hints to hydrate 
conversion 
- slightly hygroscopic 
acc. Ph. Eur. 
- formation of a lower 
hydrate 
- slightly hygroscopic 
acc. Ph. Eur. 
Solubility 
5 mg/mL > 15 mg/mL 
→ transition to A1 
> 15 mg/mL 
→ transition to A1 
Stability most stable metastable metastable 
Table 2: Physicochemical properties of the most relevant polymorphic forms A1, Ia and S2 of Cilengitide. 
 
It has been demonstrated that the anhydrous form is the thermodynamically most stable form, 
even in presence of high relative humidity. The tetrahydrate and the water-ethanol solvate 
have similar cell volumes and lattice parameters and can convert to the anhydrous form during 
storage. The anhydrous form exhibits the lowest solubility (5 mg/mL), highest melting / 
degradation temperature (onset at 304 °C), lowest hygroscopicity and highest true density 
(1.330 g/cm3) when compared to the tetrahydrate and the solvate. Due to its highest stability 
and lowest solubility, the polymorph A1 was selected for the formulation development of a 
suspension. 
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This anhydrous A1 form crystallizes in the orthorhombic space group P21 21 21 with the lattice 
parameters a = 9.7944 Å, b = 15.3877 Å and c = 19.5090 Å. Figure 5 shows the refined 
structure. 
 
Figure 5: The refined structure of the anhydrous A1 Cilengitide crystal. 
 
The entire unit cell consists of four molecules which are arranged as shown in Figure 6. The 
hydrophobic moieties of the amino acids phenylalanine and valine are outwardly orientated 
leading to a hydrophobic surface of the crystal. 
 
 
Figure 6: Arrangement of Cilengitide molecules in the unit cell of the A1 polymorph. 
 
General properties, solid-state and powder characterization of the drug substance 
 
26 
4.2 pKa values 
In the anhydrous polymorph A1, the molecules are present in a zwitterionic form and stabilized 
by two intramolecular and six intermolecular hydrogen bridges (Figure 7). 
  
Figure 7: The anhydrous A1 form of Cilengitide with two intramolecular hydrogen brigdes (left graph) and 
six intramolecular hydrogen brigdes (right graph). 
 
Two pKa values have been detected for dissolved Cilengitide molecules by potentiometric 
titration. The pKa value of 3.9 can be ascribed for the carboxylic acidic group of the aspartic 
acid and 11.1 for the guanidinium group of arginine. Thus, the calculated isoelectric point is 
around 7.5. However, measurements of the isoelectric point of suspended particles via Zeta 
and streaming potential showed a lower value of 5.5. As demonstrated in Figure 7 the arginine 
group is involved in intermolecular hydrogen bonds, and may therefore not be freely accessible 
for ionization. 
 
4.3 Particle size 
Generally, a narrow drug particle size distribution is preferred as particle size might have a 
significant impact on dissolution and absorption, mainly for compounds that show dissolution-
dependent exposure [71]. A particle size reduction might improve the exposure of a compound. 
The effect of particle size on exposure is normally assessed in animals during preclinical 
evaluation [71]. Another limitation for subcutaneous application is the needle size. A maximum 
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particle size of one third of the inner diameter is recommended [2, 12, 14]. In case for a 
25 Gauge needle this limits the particle size to 106 µm. Considering the particle shape a 
spherical shape is preferred as crystal with sharp edges or long, needle shapes may cause 
irritation or discomfort [72]. Nevertheless, there are products on the market containing needle 
shaped API particles as seen for Insuman® Basal (Sanofi Aventis) and Protaphane® Penfill 
(Novo Nordisk). 
Drug substance as obtained after synthesis and purification consists of mainly needle- and 
rod-shaped particles (Figure 8) with a typical particle size distribution summarized in Table 3. 
This particle size of up to 569 µm is too large for subcutaneous applications, the drug 
substance typically needs to be micronized. 
Non-micronized drug substance batch D(0.10) [µm] D(0.50) [µm] D(0.90) [µm] 
10/LL/017-03 6 117 366 
11/LL/112-03 52 209 569 
Table 3: Particle size distribution of the used non-micronized batches 10/LL/017-03 and 11/LL/112-03 of 
Cilengitide. 
 
 
Figure 8: Microscopic image of non-micronized Cilengitide particles (batch 10/LL/017-03) suspended in 
water (left) and SEM graph of the raw material (right). 
 
Micronization was performed with an air jet mill and reduced the particle size to the desired 
size of 1.2 - 1.3 µm for D(0.10), 6 - 7 µm for D(0.50) and 15 - 18 µm for D(0.90). Nevertheless, 
a few large needles of up to a length of 100 µm are still present. (Figure 9). 
 
200 µm 
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Figure 9: Microscopic image of micronized Cilengitide particles (batch 10/LL/017-03) suspended in water 
(left) and SEM graph of the raw material (right).  
 
200 µm 
200 µm 
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4.4 Flow properties of raw material 
The addition of the solid material from the bulk storage container to the liquid phase is an 
essential process step during suspension manufacturing. Therefore, raw materials with 
acceptable flow properties are preferred to avoid difficulties, e.g. powder loss, powder sticking 
to the wall and intersection of the container. The bulk flow properties of non-micronized and 
micronized drug substance were characterized using the methods for powder characterization 
of the Ph. Eur. (Table 4). The non-micronized material offers “good” flow character considering 
the Hausner ratio (Ph. Eur). The observed angle of repose also confirms “fair” flowability 
without any aid (Ph. Eur.). However, the flow properties of the micronized drug are inferior. 
The flowability is “very, very poor” (Ph. Eur.) according to the determined Hausner ratio. The 
determination of the angle of repose and the flowability through an orifice is not feasible even 
with the help of the agitator. 
 
Parameter 
Non-micronized drug 
substance 
Micronized drug substance 
Bulk density 0.61 ± 0.02 g/mL 0.24 ± 0.01 g/mL 
Tapped density 0.67 ± 0.01 g/mL 0.42 ± 0.00 g/mL 
Hausner ratio 1.11 ± 0.01 1.62 ± 0.01 
Angle of repose 37.3 ± 0.4 ° - 
Flow through an orifice 3.65 ± 0.17 s - 
Table 4: Characteristic flowability parameter for non-micronized and micronized drug substance. 
 
In conclusion, the non-micronized raw material flows good in contrast to the micronized 
powder. However, the particle size of the non-micronized material is too large for an application 
via a 25 Gauge needle. 
 
4.5 Conclusion 
The anhydrous polymorph A1 of Cilengitide is the most stable form and thus, suitable for the 
development of a suspension formulation. The solubility of the compound is approximately 
5 mg/mL API in water and the isoelectric point at pH 5.5. The surface of the API particle is 
hydrophobic due to the outwardly orientated phenylalanine and valine group. The non-
micronized material contains needle- and rod-shaped particles offering good flowability 
contrary to the micronized powder. However, the particle size of the non-micronized API is too 
large for an application with a 25 Gauge needle.  
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5 Characterization of aqueous Cilengitide suspension 
5.1 Parameters influencing the particle size 
Generally, the particle size of a preclinical parenteral suspension formulation may impact drug 
absorption [71]. For poor soluble compounds a narrow particle size distribution is preferred 
with particles below 10 µm [71]. However, for drugs with a solubility higher than 1 mg/mL, as 
in the case of Cilengitide, particle size has low impact on dissolution or bioavailability, 
respectively [71]. In this case the size is mainly limited by the administration via a needle. A 
maximum particle size of one third of the needle diameter is recommended as larger particles 
can block the needle during injection [2, 12, 14]. For a 25 Gauge needle with an inner diameter 
of 0.318 mm the maximum particle size should be below 100 µm. Furthermore, a narrow 
particle size distribution is preferred with respect to storage stability. For Cilengitide particles, 
a particle size distribution of 2 D(0.10), 6 D(0.50), 24 D(0.90) and 35 D(0.95) µm is specified 
for the micronized raw material. In comparison, an injectable depot formulation comprising 
Iloperidone crystals shows a drug particle size of 15 to 70 µm [73]. The anti-inflammatory 
suspension Volon® for intramuscular application exhibits a Triamcinolonacetonide D(0.50) 
value of 10 µm and D(0.90) value of 47 µm, respectively [74]. The insulin product Insuman® 
Basal contains drug particles of 2.5 µm (D(0.10)), 10 µm (D(0.50)) and 26 µm (D(0.90)) and 
Protaphane® Penfill particles of 1.4 µm ((D(0.10)), 5.1 µm (D(0.50)), 13 µm D(0.90)). 
In the following part the use of non-micronized versus micronized material is evaluated with 
respect to the particle size. The non-micronized material offers the advantage of better flow 
properties and thus, easier handling for production. The influence of stirring time and mode in 
aqueous medium upon dispersing is analyzed as well as the effect of Cilengitide concentration. 
The storage stability is determined at different conditions over a period of one year. The particle 
size is measured by laser diffraction. Furthermore, microscopy complements the data and 
enables the characterization of the agglomeration behavior and the inner structure of the 
suspension. 
 
5.1.1 Stirring time and raw material particle size 
The non-micronized raw material with particles up to 700 µm has better flow properties and 
shows a lower tendency for electrostatic charges. Therefore, it has been evaluated if the 
particle size can be reduced to the recommended maximum size of approximately 100 µm by 
stirring during the suspension manufacture. The influence of stirring is also analyzed for 
suspensions with micronized material. 
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In suspensions containing non-micronized raw material the particle size decreases during 
stirring up to 48 hours as a function of time (Figure 10). After 48 hours of stirring, a particle 
size distribution similar to micronized raw material is detected. The D(0.95) value is reduced 
to 28.5 µm after 48 hours of stirring. 
 
 
Figure 10: Particle size distribution of suspensions with 60 mg/mL non-micronized material in WfI as a 
function of stirring time. Error bars represent standard deviations from triplicate measurements. 
 
The particle size of suspensions with micronized raw material is less affected by the stirring 
process. Only the largest particles are reduced in size within the first four hours as indicated 
by the decrease of the D(0.95) by around 10 µm with a D(0.95) of 35.5 µm after 24 hours. 
 
 
Figure 11: Particle size distribution of suspensions with 60 mg/mL micronized material in WfI as a function 
of stirring time. Error bars represent standard deviations from triplicate measurements. 
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It is not possible to determine the particle size immediately after addition to water due to an 
inhomogeneous distribution. Comparing the particle size of the micronized raw material with 
an aqueous suspension after one hour of stirring (Table 5) indicates slightly larger sizes. This 
is due to still present agglomerates. 
 
D(0.05) 
[µm] 
D(0.10) 
[µm] 
D(0.50) 
[µm] 
D(0.90) 
[µm] 
D(0.95) 
[µm] 
Raw material - 2 6 24 35 
After 1 hour 
stirring 
1.3 2.4 11.3 33.7 47.2 
Table 5: Comparison of particle size distribution of micronized raw material and of suspensions (60 mg/mL) 
after 1 hour of stirring. 
 
The micrographs of suspensions prepared with micronized drug (Figure 12) indicate structural 
changes during stirring. Starting with inhomogeneously distributed particles and lumps the 
dispersion becomes more homogeneous with increasing stirring time. After four hours the 
smaller particles are attached to the larger ones and a continuous, scaffold-like structure is 
formed. A homogeneous distribution of lower (30 mg/mL) and higher (90 mg/mL) concentrated 
suspensions is also seen after 4 hours of stirring by microscopy. 
 
Figure 12: Micronized particles suspended in WfI (60 mg/mL) at different stirring times (A) 0.5 min, (B) 5 min, 
(C) 20 min, (D) 4 h. 
 
200 µm 
 
200 µm 
 
200 µm 
A B 
D C 
 
200 µm 
Characterization of aqueous Cilengitide suspension 
33 
 
This continuous inner structure is also observed for the non-micronized material after 24 hours 
of stirring (Figure 13 D), corresponding to the similar particle sizes measured by laser 
diffraction. The non-micronized particles are initially separated before they become reduced in 
size and interact with each other to form this continuous structure. 
 
 
Figure 13: Non-micronized particles (60 mg/mL) suspended in WfI after different stirring times (A) 0.5 min, 
(B) 30 min, (C) 4 h, (D) 24 h. 
 
There are two possible mechanisms which can lead to the notable particle size decrease of 
the non-micronized suspension during stirring. On the one hand, particle dissolution can cause 
the size decrease. On the other hand, the particles might be comminuted by the mechanical 
energy imparted by the magnetic stirrer. If solution processes were mainly responsible for the 
observed reduction, the smallest particles would disappear resulting in an increase of the 
particle size distribution and the particles would not further decrease after the saturation level 
of the dispersion medium is reached. Furthermore, less particle size changes are expected for 
a higher concentrated suspension as a lower relative percentage is dissolved. On the other 
hand, particles suspended in a saturated solution would be comminuted to a comparable 
extend as seen in unsaturated medium if the decrease is mainly induced by mechanical 
energy. 
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To gain further insight on the mechanism of particle size decrease, the solubility of Cilengitide 
in water is determined as a function of time. Furthermore, non-micronized material (60 mg/mL) 
is suspended in a saturated API solution and stirred for 48 hours. The particle size distribution 
of a 300 mg/mL suspension over time is determined. Additionally, individual large particles 
were dispersed in different media WfI, a non-saturated and saturated Cilengitide solution in a 
flat cuvette and observed by stereomicroscopy without stirring. The final saturation solubility 
of Cilengitide in water is already reached after 5 min indicating that size reduction is 
mechanically induced (Figure 14). 
 
Figure 14: Solubility of Cilengitide in WfI as a function of time. Error bars represent standard deviations 
from triplicate measurements. 
 
Figure 15 A shows the particle size of 60 mg/mL API suspended in a saturated API solution as 
a function of stirring time. A similar particle size reduction is observed as for API particles 
suspended in water (Figure 10) demonstrating that mechanical size reduction prevails. For 
higher concentrated suspension, the absolute sizes cannot be compared as different raw 
material batches were used. Nevertheless, a similar trend is observed for particle size 
reduction of the concentrated suspension as for the lower concentrated (Figure 15 B). 
 
Figure 15: Particle size distribution of suspensions with 60 mg/mL non-micronized material in saturated 
API-solution (A) and of suspensions with 300 mg/mL non-micronized material in WfI (B) as a function of 
stirring time. Error bars represent standard deviations from triplicate measurements. 
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A particle size distribution similar to the micronized powder is reached after 48 hours of stirring 
of 300 mg/mL as already seen for the 60 mg/mL suspensions in water (Table 6). When a non-
micronized single particle is suspended in a non-stirred saturated API-solution the particle size 
and appearance do not change after 16 days (Figure 16). 
 60 mg/mL API 300 mg/mL API 
Micronized 
raw material 
D(0.05) [µm] 1.23 ± 0.07 1.59 ± 0.08 1.35 
D(0.10) [µm] 4.28 ± 0.23 5.19 ± 0.18 1.81 
D(0.50) [µm] 12.05 ± 0.69 14.60 ± 0.86 6.14 
D(0.90) [µm] 23.99 ± 1.74 32.93 ± 4.85 24.16 
D(0.95) [µm] 28.48 ± 2.23 41.55 ± 7.77 35.19 
Table 6: Particle size distribution of suspension with 60 and 300 mg/mL micronized API stirred for 48 hours 
and the micronized raw material powder. Standard deviations are from triplicate measurements. 
 
 
Figure 16: Non-micronized Cilengitide crystal in saturated API-solution at the beginning (A) and after 
16 days (B). 
 
In conclusion, all of the above mentioned results indicate that the dissolution process is not 
responsible for the substantial size reduction of Cilengitide particles upon dispersion in 
aqueous media. Instead the particles are reduced by the mechanical input of stirring. The 
particle size distribution of non-micronized material in suspension becomes similar to the size 
distribution of micronized drug substance raw material as well as of micronized substance in 
suspension. It can be speculated that the non-micronized particles are fragmented at 
predetermined breaking points either during stirring in suspension or jet-milling of the drug 
material. Stereomicrographs of a particle suspended in water show the formation of such 
predetermined breaking points during the solution (Figure 17). 
 
 
 
A B 
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Figure 17: Non-micronized Cilengitide crystal in WfI at the beginning (A), after 3.5 h (B), 5.25 h (C) and 8 h 
(D) of incubation.  
 
A similar process occurs when a particle was suspended in a non-saturated API-solution. The 
particle dissolves and further, predetermined breaking points appear (Figure 18). 
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Figure 18: Non-micronized Cilengitide crystal in API-solution (4 mg/mL) at the beginning (A), after 3 d of 
storage (B), 8 d (C) and 12 d (D) of incubation. 
 
5.1.2 Application of comminuting methods with higher energy levels 
Additionally it was to be analyzed whether the application of high energy comminution leads 
to smaller particle sizes. For this purpose, suspensions containing micronized material that 
were stirred for 24 hours were additionally treated by either ultrasound (Sonotrode) or 
Ultraturrax for 30 s. Both treatment methods result in only a minimal decrease in particle size 
(Table 7). 
 
 
Micronized, 
24 h stirring 
Micronized, 
ultrasound (30 s) 
Micronized, 
Ultraturrax (30 s) 
D(0.05) [µm] 1.35 1.23 1.24 
D(0.10) [µm] 2.81 2.75 2.81 
D(0.50) [µm] 13.16 10.91 10.90 
D(0.90) [µm] 29.21 26.85 26.66 
D(0.95) [µm] 35.54 34.67 34.22 
Table 7: Particle size distribution of suspensions with 300 mg/mL micronized API after 24 h stirring and 
with ultrasound or Ultraturrax application. 
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As an alternative, suspensions with micronized raw material were ball milled. Only a slight but 
significant size reduction, especially of the larger particles (D(0.90) and D(0.95)) by milling with 
1 mm for 10 min, is resulted (Figure 19). Smaller particles (D(0.10)) are not reduced in size. 
Milling with the larger balls does not affect the particle size distribution. Longer milling times 
could not be investigated as the suspension foams substantially. 
 
Figure 19: Particle size distribution of suspension with 300 mg/mL micronized API without milling (■) and 
after milling with 5 mm balls for 10 min (▲) or with 1 mm balls for 10 min (●), respectively. Error bars 
represent standard deviations from triplicate measurements. 
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5.1.3 Influence of drug substance concentration in suspension 
The above mentioned results have shown that stirring with a magnetic stirrer strongly affects 
the particle size of suspensions with non-micronized raw material. However, the particle size 
of suspensions containing micronized API is hardly influenced by stirring and only slightly by 
ball-milling. In this part the influence of concentration on the final particle size of suspensions 
containing 30, 100 and 300 mg/mL micronized API after 4 h of stirring is analyzed. The results 
demonstrate that the size distribution of the lower concentrated suspension (30 and 
100 mg/mL) is similar (Figure 20). The suspension containing 300 mg/mL API yields smaller 
particle sizes for the D(0.90) and D(0.95). The largest particles comminution may be more 
effective for higher concentration due to higher internal friction. 
 
 
Figure 20: Particle size distribution of suspension with 30 mg/mL (■), 100 mg/mL (▲) and 300 mg/mL (●) 
micronized API. 
 
 
5.2 Particle size stability upon storage 
Particle size stability during storage is a crucial parameter for suspension development. As 
already mentioned before, large particles can compromise the injectability, physiological 
compatibility and dissolution kinetics. A wide particle size distribution can promote a particle 
size increase during storage [75] with a particle growth of the larger particles at the expense 
of smaller ones (Ostwald ripening). The temperature [75] and the volume fraction [76] can 
affect the ripening rate. 
The stability of several formulations is analyzed at 2 – 8 °C over a time period of one year. The 
influence of the raw material (non-micronized stirred for 48 h in suspension versus micronized 
stirred for 4 h in suspension) besides the concentration is determined. The suspensions 
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containing 300 mg/mL micronized raw material are additionally stored at accelerated 
conditions for 4 weeks at 40 °C / 75 % r.H. or 9 weeks at 25 °C / 60 % r.H. Finally, the effect 
of beads on particle size during storage is analyzed for suspensions containing 300 mg/mL 
micronized Cilengitide. Three metal beads (2 mm diameter) per vial are added to facilitate the 
resuspension of the highly concentrated suspension. 
 
The analyses over one year show good particle size stability for suspensions containing 
300 mg/mL non-micronized API (Figure 21). The smallest particles (D(0.05)) grow about 
0.2 µm (within one year) which means a percentage increase of 12 %. The D(0.95) value rises 
by about 4 µm corresponding to a percentage increase of 10 %. 
 
 
Figure 21: Particle size stability of suspensions containing 300 mg/mL non-micronized API stored at 
2 - 8 °C over one year. 
 
Compared to these results the change in particle size distribution of samples containing 
micronized raw material is more pronounced. The increase of the D(0.05) value is about 
0.2 µm (16 %), the D(0.95) value rises by about 11 µm (31 %) within one year. However, the 
increase is still acceptable as neither the syringeability nor the injectability are compromised. 
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Figure 22: Particle size stability of suspensions containing 300 mg/mL micronized API stored at 2 - 8 °C over 
one year. 
 
Even under accelerated storage conditions the particle size does not increase significantly 
(Table 8). The smallest particles (D(0.05)) do not change in size, the D(0.95) value is about 
2 µm (5 %) higher at 40 °C / 75 % r.H. than the value after suspension storage at 2 – 8 °C for 
4 weeks. Considering the storage at 25 °C / 60 % r.H. for 9 weeks the D(0.05) value rises by 
about 0.14 µm (10 %). The larger particles grow about 6 µm more which corresponds to a 
percentage increase of 16 %. 
 
 D(0.05) [µm] D(0.10) [µm] D(0.50) [µm] D(0.90) [µm] D(0.95) [µm] 
Start 1.33 ± 0.02 2.84 ± 0.14 12.47 ± 0.35 30.95 ± 0.63 39.42 ± 0.79 
4 weeks,  
2 – 8 °C 
1.46 ± 0.04 3.91 ± 0.11 14.19 ± 0.19 31.50 ± 0.57 38.37 ± 0.79 
4 weeks,  
40 °C / 75% r.H. 
1.40 ± 0.02 3.93 ± 0.12 14.41 ± 0.24 32.68 ± 0.12 40.16 ± 0.16 
8 weeks,  
2 – 8 °C 
1.42 ± 0.14 3.65 ± 0.40 12.74 ± 0.42 29.34 ± 2.18 36.93 ± 2.87 
9 weeks,  
25 °C / 60% r.H. 
1.56 ± 0.11 4.23 ± 0.18 14.84 ± 0.33 34.07 ± 0.90 42.42 ± 1.96 
Table 8: Particle size distribution of suspension with 300 mg/mL micronized API stored at accelerated 
conditions. 
 
Studying the influence of the concentration on the storage stability it can be noted that the 
D(0.95) values increase is similar with 9 µm increase for the 30 mg/mL suspension and 11  µm 
for the 100 and 300 mg/mL suspension (Figure 23). 
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Figure 23: Particle size stability of suspensions containing 30 mg/mL (A), 100 mg/mL (B) and 300 mg/mL (C) 
micronized API stored at 2 – 8 °C over 1 year. D(0.05) (■), D(0.10) (▲), D(0.50) (●), D(0.90) (□) and D(0.95) (∆) 
are shown. 
 
For the evaluation of the influence of metal beads on the particle size, D(0.10), D(0.50), D(0.90) 
and D(0.95) values are shown in Figure 24. The beads do not influence the particle size 
distribution over the storage period. 
 
 
Figure 24: Particle size stability of suspensions with 300 mg/mL micronized API stored at 2 – 8 °C over 
1 year with beads (─) and without beads (- -). D(0.10) (□), D(0.50) (■), D(0.90) (▲) and D(0.95) (●) are shown. 
 
In summary, it can be noted that the suspended particles offer good size stability when stored 
over a period of one year or at accelerated conditions independent of the used raw material 
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and concentration. The final particle size of suspensions prepared with non-micronized raw 
material remarkably depends on the stirring time. Although a similar particle size compared to 
micronized raw material can be reached with the non-micronized material, long stirring times 
(48 hours) are needed which is not acceptable for a sterile manufacturing process. Thus, it 
was decided to use micronized material for future experiments although the material exhibit 
drawbacks with regard to flow properties. A stirring time of 4 hours of stirring is defined to 
obtain a homogeneous suspension with a continuous, scaffold-like structure using the 
micronized material. It should also be noted that the size of the micronized particles is less 
affected by application of ultrasound, Ultraturrax or additional short-time ball-milling. 
 
 
5.3 Sedimentation behavior 
The sedimentation rate of the suspended particles should be low to avoid resuspension 
difficulties during storage and to ensure the withdrawal of adequate doses after resuspension. 
Generally, there are two types of sedimentation behavior. On the one hand, agglomerated 
particles settle as flocs building a loosely packed sediment with a minimized caking risk. On 
the other hand, deflocculated particles settle as separated particles. The sedimentation rate of 
the latter is usually slower but a densely packed sediment is built which can cause difficulties 
in redispersing (caking). From microscopic pictures it is known that the suspended micronized 
Cilengitide particles interact with each other building a scaffold-like structure. Thus, it is 
expected that the particles settle as flocs. However, the sediment can be compressed during 
storage by the particles´ own weight due to the large particle size, so the caking potential has 
to be analyzed. 
The sedimentation rate is analyzed by measuring the transmission and backscattering of a 
near infrared diode as a function of the sample height. Thus, a fingerprint is obtained at given 
time points for a more detailed analysis. Measurement of the sedimentation rate was limited 
to a maximum API-concentration of 150 mg/mL. Photographs are taken at different time points 
using API concentrations of 15, 30 and 100 mg/mL. The caking potential of 300 mg/mL 
suspensions is determined by the evaluation of the sedimentation degree F. F is defined by 
the ratio of the sediment volume Ve after 52 weeks of storage to the sediment volume V0 at the 
beginning (equal to overall volume for the 300 mg/mL suspension). 
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5.3.1 Sedimentation rate analyzed by transmission and backscattering detection 
Figure 25 shows the results of the transmission and backscattering measurements of 
suspensions with 150 mg/mL API during 13 hours. The curves demonstrate the profiles at 
different time points. The transmission of the sample at 37.7 – 39.5 mm sample height 
increases up to 30 % after 13 hours (red curve) which indicates that the particles settle and a 
small more translucent supernatant is detected. The calculated sedimentation rate is 
1.7 µm/min. The transmission increase goes ahead with a backscattering decrease at the 
mentioned sample height. However, a marginal increase of the backscattering is observed at 
the lower and middle zone of the cuvette, indicating that the sediment is becoming more 
concentrated. No distinct change at the vial bottom can be identified. 
 
 
Figure 25: Transmission and backscattering profile of suspension with 150 mg/mL micronized API 
dependent on time over the sample height. 
 
As discussed in chapter 5.4 an acceptable time for drawing out the suspension is 20 s. Within 
this time the particles should not show sedimentation. Considering the calculated 
sedimentation rate, the travelling distance would be 0.57 µm within 20 s. It can be concluded 
that the low settling rate does not compromise an adequate dosing even of the half 
concentrated 150 mg/mL suspension. The sedimentation rate of the double concentrated 
suspension is expected to be lower due to the increased steric hindrance of the particles. This 
is confirmed by the evaluation of the sedimentation degree during storage as discussed in the 
following. 
 
5.3.2 Macroscopic sedimentation behavior 
Deflocculated suspensions are characterized by separated particles which settle independent 
from each other. The larger particles sediment faster than the smaller, resulting in a turbid 
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supernatant until all particles are sedimented. However, flocculated particles settle as flocs 
with a clear supernatant as the smaller particles are attached to the larger. A settling particle 
front is visible for this type. 
For the evaluation of the sedimentation behavior suspensions with 15, 30, 100 and 300 mg/mL 
are observed. The lower concentrations enable a better analysis. The samples are analyzed 
over a period of 24 hours, significant time points of each concentration are presented. 
In 15 mg/mL suspensions the particles are homogeneously distributed at the beginning (Figure 
26, “start”). Already after 1 minute, most particles have sedimented and only the smallest 
particles stay suspended. After 20 minutes, the supernatant is almost clear. The sedimentation 
is too fast to gain information about the sedimentation behavior (flocculated / separated 
particles). Nevertheless, a magnification of the suspended particles suggests that they are 
flocculated. 
 
  
Figure 26: Sedimentation behavior of suspension with 15 mg/mL API at different time points. 
 
In suspensions with 30 mg/mL the supernatant quickly becomes clear and the sediment height 
reduces with time. The particles settle rapidly as flocs (Figure 27, 1 and 2 min). Only few 
separated, smaller particles sediment more slowly resulting in supernatant clarification with 
time. 
 
 
Figure 27: Sedimentation behavior of suspension with 30 mg/mL API at different time points. 
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The sedimentation of the higher concentrated samples (100 mg/mL) is hindered due to the 
higher solid fraction. Only a small supernatant becomes visible after 5 minutes. After one hour, 
the sediment volume is marginally decreased and a loosely packed sediment is observed. 
 
 
Figure 28: Sedimentation behavior of suspensions with 100 mg/mL API at different time points. 
 
The 300 mg/mL samples only show a minimal supernatant formation after 12 weeks of storage. 
 
 
Figure 29: Sedimentation behavior of suspension with 300 mg/mL API at different time points. 
 
The calculation of the sedimentation degree (ratio sediment height / total suspension height) 
of the 300 mg/mL suspension during storage confirms the decreasing sedimentation rate with 
concentration increase. The graph shows a high, more or less constant sedimentation degree 
during storage. Over 8 weeks of storage no sedimentation occurs (sedimentation degree of 
1.00 ± 0.01). After 12 weeks, a supernatant becomes visible and a sedimentation degree of 
0.95 ± 0.01 was seen. After one year the sedimentation degree yields 0.86 ± 0.03. Thus, 
regarding the sedimentation rate there is no need for optimization. The sedimentation of the 
100 and 300 mg/mL Cilengitide suspension is very slow so that an adequate withdrawal of the 
required dose is ensured during handling. The particles settle as flocs, building a loose 
sediment. 
Additionally, the time needed to resuspend the Cilengitide suspensions with 30, 100 and 
300 mg/mL is analyzed during storage over one year (2 - 8 °C). The low concentrated 
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suspensions with 30 mg/mL require approximately 10 ± 2 min for resuspension already after 
1 week storage (Figure 30). With longer storage this time varies slightly but remains high and 
reaches approximately 13 minutes after 52 weeks. The long resuspension is due to a fast 
sedimentation of the particles building a compact cake. Suspensions with 100 mg/mL API need 
approximately 6 ± 1.3 min for resuspension after 1 week. Storage time does not affect the 
required time. Resuspension time of 300 mg/mL formulations stays below 5 minutes for up to 
8 weeks storage due to the slow sedimentation. Subsequently, the time increases up to 
approximately 15 minutes after 52 weeks of storage. This significant increase is due to the 
more compact sediment described above and the resuspension of the highly concentrated 
aqueous suspension is affected by the high viscosity which increases the required time. 
 
 
Figure 30: Time needed for resuspension of suspensions with 30 mg/mL (black), 100 mg/mL (white) and 
300 mg/mL (grey) API as a function of storage time. 
 
 
5.4 Rheological characterization 
The before mentioned results indicate a good physical stability of the particles in water, even 
at 300 mg/mL API. But the highest concentrated suspension of micronized particles is a very 
viscous, paste-like system. As a result, difficulties with resuspendability and syringeability can 
occur. For this purpose, the rheological properties are determined over a shear range of 
ẙ = 0.1 - 1000 1/s at the different API concentrations. It is expected to observe a viscosity 
increase with higher solid fraction. Highly concentrated suspensions usually behave as non-
Newtonian fluid, offering shear-thinning or shear-thickening characteristics. It is analyzed if a 
yield point exists for the suspensions. The thixotropy is quantified by calculating the area 
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between the for- and back-curve (hysteresis area). Finally, the viscosity results are translated 
into the formulation performance in terms of syringeability, injectability and resuspendability. 
For this purpose, shear rates have to be defined which represent the above mentioned 
performance parameter as the viscosity depends on the applied shear rate (non-Newtonian 
behavior). The shear rate ẙ can be calculated by using the following approximation [4] where 
Q is the volumetric flow rate and R the inner radius of the needle [Eq. 11]. 
ẙ = 4 𝑄/𝜋𝑅3 [Eq. 11] 
 
A 25 Gauge needle is used for drawing up and injecting the suspension. The passage of the 
300 mg/mL suspension through a 25 Gauge needle is not an issue as the particles are small 
enough and the required force during injection low. However, the flow of the suspension down 
the vial into the cannula is limited due to the high viscosity. For an acceptable syringeability a 
volume stream of Q = 0.05 mL/s (1 mL volume within 20 s) is required [4]. By flowing down the 
vial (r = 6.5 mm) with the required volume stream of 0.05 mL/s a shear rate of ẙ = 0.23 s-1 is 
applied to the formulation according to the above mentioned equation. For further discussion 
of the viscosity, special attention is paid to this shear rate of ẙ = 0.23 s-1. As the characterization 
at low shear rates is difficult due to the heterogeneous nature of the suspension and possible 
slip, higher shear rates, such as ẙ > 5 1/s are recommended [28]. Consequently, the viscosity 
value at ẙ = 12.6 s-1 is also used to assess the syringeability ensuring the required 
measurement quality for all samples. Additionally, the data variability is low for all the 
mentioned samples at ẙ = 12.6 s-1. Regarding the injectability with a 25 Gauge needle 
(0.318 mm diameter) or smaller when forcing the suspension through the needle, shear rates 
higher than 1000 s-1 are applied to the systems according by the calculation and confirmed by 
Miller et. al [4]. 
 
5.4.1 Influence of concentration on rheological properties 
The analyses of the suspensions viscosity at ẙ = 0.1 – 1000 1/s containing 30, 100, 200 and 
300 mg/mL of micronized raw material demonstrates the expected viscosity increase with 
higher API content (Figure 31).  
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Figure 31: Viscosity of suspensions containing 30 mg/mL (□), 100 mg/mL (■), 200 mg/mL (▲) and 300 mg/mL 
(●) micronized API as a function of shear rate. Error bars represent standard deviations from triplicate 
measurements. 
 
Regarding the lowest concentrated formulations (30 mg/mL) the flow behavior corresponds to 
Newtonian fluid over a broad shear range (300 < ẙ <1000 1/s). Shear-thinning characteristics 
are only observed at shear rates lower than 300 1/s. The samples are comparable to water 
with a viscosity of 1 mPas at ẙ > 100 1/s. Increasing the concentration to 100 mg/mL, the 
viscosity increases and the formulations show pseudoplastic flow. At shear rates higher than 
400 1/s, the viscosity is almost independent of the shear rate at approximately 4 mPas. 
It is conspicuous that the suspensions with 100 mg/mL API exhibit a viscosity maximum at 
about 25 1/s (increasing shear rates) or 50 1/s (decreasing shear rates), respectively (Figure 
32). This maximum might be caused by an initial shear thinning with the particles orientating 
in the shear plane [77]. Subsequently the particle-particle interaction becomes a dominating 
factor, increasing the viscosity. 
 
Figure 32: Viscosity of suspensions with 100 mg/mL micronized API as a function of shear rate. Error bars 
represent standard deviations from triplicate measurements. 
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When the API concentration is increased to 200 or 300 mg/mL, the viscosity is significantly 
increased. At lower shear rates, the viscosity strongly increases pointing to the formation of a 
yield point and a solid like behavior in quiescent conditions. At ẙ = 0.23 1/s the 300 mg/mL 
formulations yield a viscosity of 48.1 ± 39.9 Pas. In comparison, the 200 mg/mL suspensions 
exhibit a value of 2.80 ± 2.53 Pas, 0.155 ± 0.09 Pas is detected for 100 mg/mL formulations 
and 0.094 ± 0.10 Pas for 30 mg/mL samples. This is confirmed by the observation that the 
300 mg/mL formulation does not flow when the vial is turned upside down (Figure 33). The 
200 and 300 mg/mL formulations show typical non-Newtonian behavior with remarkable shear-
thinning characteristics. Already at ẙ = 12.6 1/s the viscosity is significantly reduced to 
0.58 ± 0.08 Pas for the 300 mg/mL and 0.14 ± 0.02 Pas for the 200 mg/mL suspensions. 
Shear-thickening or a viscosity maximum is not observed in contrast to the 100 mg/mL 
formulation. This could be due to a lower interparticle distance and a continuous inner structure 
at 200 mg/mL and more already at the start. The inner structure is destroyed by shearing, 
resulting in the observed shear-thinning characteristics over the whole shear rate range. At a 
shear rate of ẙ = 1000 1/s, which represents the injection with a cannula, the 200 and the 
300 mg/mL samples show a viscosity value of 0.01 ± 0.001 Pas and 0.04 ± 0.004 Pas, 
respectively. 
 
 
Figure 33: Flow behavior of a suspension with 300 mg/mL micronized API when vial is turned upside down. 
 
Regarding the shear stress, the 30 and 100 mg/mL concentrated suspensions do not exhibit 
a relevant yield point (30 mg/mL: Τ0 = 0.025 Pa, r = 0.9994; 100 mg/mL: Τ0 = 0.404 Pa, 
r = 0.9903, fitted to the Casson model). Also for 200 mg/mL containing suspension, a possible 
apparent yield point is low (Τ0 = 2.50 Pa, r = 0.9655). For suspension with the highest amount 
of API, the calculated yield point is 9.92 Pa (r = 0.9680). However, the calculation might depend 
on the used model and it is usually required to confirm the calculations using alternative 
measurement methods such as measurements of creep. 
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Finally, the thixotropic behavior is evaluated by calculation of the hysteresis areas (Table 9). 
The hysteresis area increases with increasing API concentration. Overall, the hysteresis effect 
is small despite a pronounced shear thinning. In practice this means that the viscosity is 
temporarily lowered by shaking, but the suspensions return to a higher viscous system during 
drawing out the suspension from the vial. 
 
API-concentration 30 mg/mL 100 mg/mL 200 mg/mL 300 mg/mL 
Hysteresis area 
[Pa/s] 
46.8 ± 15.1 224.5 ± 49.4 672.4 ± 76.5 2406 ± 819.9 
Table 9: Calculated hysteresis area of suspensions with 30 mg/mL, 100 mg/mL, 200 mg/mL and 300 mg/mL 
micronized API. 
 
 
Figure 34: Viscosity of suspensions containing 30 mg/mL (□), 100 mg/mL (■), 200 mg/mL (▲) and 300 mg/mL 
(●) micronized API as a function of shear (forward and backward shearing). Error bars represent standard 
deviations from triplicate measurements. 
 
5.5 Injectability of different concentrated formulations 
The injectability was investigated using a texture analyzer set up. The force needed for the 
injection of the formulation via a 25, 26 or 27 Gauge needle, respectively, is quantified. The 
results demonstrate that all the concentrations can be injected at acceptable forces using a 
27 G needle or larger (Figure 35). The required force increases with increasing API 
concentrations up to 2.72 ± 0.14 N (25 G needle). The force measured for the injection of the 
300 mg/mL suspension via the smaller 27 Gauge needle is higher (4.8 N), but still acceptable. 
But needle blockage occurred for one sample with a 27 Gauge needle. 
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Figure 35: Injection force required for suspensions containing 7 mg/mL, 30 mg/mL, 100 mg/mL, 150 mg/mL 
or 300 mg/mL micronized API using a 25 (black), 26 (white) and 27 Gauge (greey) needle, a volume of 1 mL 
and a speed of 10 mm/s. Error bars represent standard deviations from triplicate measurements. 
 
The mentioned injectability results correspond to viscosity measurements demonstrating the 
extreme shear-thinning character of the suspensions. The shear rates during injection are 
higher than 1000 1/s as discussed before. In this high shear range even the highly 
concentrated suspensions offer an acceptable low viscosity (about 40 mPas) and thus, a low 
force is needed for injection. In literature, a viscosity lower than 50 mPas is required to apply 
a formulation subcutaneously with a 25 to 27 Gauge needle [4]. 
 
5.6 Conclusion 
Summing up, the viscosity at low shear rates is significantly higher for suspensions with 
300 mg/mL than for formulations of 30, 100 or 200 mg/mL Cilengitide. The 200 and 300 mg/mL 
formulations show a yield point and behave like a solid with poor flow. Consequently, the 
syringeability is hindered as the 300 mg/mL suspension does not flow into the cannula. 
Suspensions with 200 and 300 mg/mL API are remarkable shear-thinning systems offering a 
significantly lowered viscosity at high shear rates so that injection via a needle is feasible. The 
suspended Cilengitide particles interact with each other, as seen by micrographs, building a 
continuous, scaffold-like structure that increases the viscosity. A very low sedimentation rate 
is observed for the 300 mg/mL suspensions and marginal supernatant quantities are seen only 
after 12 weeks of storage. Stability problems in the form of caking did not occur due to the high 
sedimentation degree. Also the particle size distribution was stable during storage for 1 year. 
Particle sizes comparable to the micronized raw material are obtained when non-micronized 
material is stirred in suspension for 2 days. Micronized material is used for further formulation 
0
1
2
3
4
5
6
7 30 100 150 300
F
o
rc
e
 [
N
]
API concentration [mg/mL]
Characterization of aqueous Cilengitide suspension 
53 
development to reduce manufacturing time and to ensure consistent particle size distributions 
of the product. 
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6 Formulation development for 300 mg/mL Cilengitide suspensions 
6.1 Parameters influencing the suspension viscosity 
As previously outlined, the viscosity of a suspension can be influenced by several parameters 
including pH, ions, particle size and the addition of surfactants. The potential of these 
formulation approaches to reduce the viscosity of a 300 mg/mL Cilengitide suspension is 
analyzed and discussed in the following chapters. 
 
6.1.1 Effect of varying pH on viscosity of 300 mg/mL API suspension 
The variation of pH can influence the viscosity by changing the repulsive electrostatic forces 
while attractive Van der Waals forces remain constant. Therefore, it is expected to detect the 
highest viscosity around the isoelectric point where repulsive forces are minimal and the 
hydrophobic forces dominate, whereas the viscosity should be reduced by electrostatic forces 
at higher and lower pH values. A pH range from 4 to 9 is considered which is physiologically 
acceptable for a subcutaneous injection [78] and feasible with respect to the API chemical 
stability [79, 80]. 
The result at ẙ = 0.2 1/s shows that the viscosity is influenced by pH variation (Figure 36). At 
pH 5.5 the suspension tends to exhibit the highest viscosity. This difference is significant when 
compared to pH 7.5 and higher and insignificant when compared to pH 4 and 5 due to the high 
standard deviations at these low pH values (p < 0.05). 
 
 
Figure 36: Influence of pH on viscosity of 300 mg/mL API in WfI at ẙ = 0.2 1/s. Error bars represent standard 
deviations from triplicate measurements. 
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The same trend is observed at a higher shear rate of ẙ = 12.6 1/s with significant differences 
(p < 0.05) between suspensions with pH 5.5, 6 and 6.5 on the one hand and suspensions with 
7.5 and higher on the other hand (Figure 37). 
 
Figure 37: Influence of pH on viscosity of 300 mg/mL API in WfI at ẙ = 12.6 1/s. Error bars represent standard 
deviations from triplicate measurements. 
 
From Zeta potential measurements it is known that the IEP of Cilengitide particles suspended 
in water is around pH 5.5 (Figure 38). It is conspicuous that the isoelectric point of the 
suspended particles is lower compared to the calculated IEP (IEPcalculated ~ 7). As demonstrated 
in chapter 4.2 the arginine group is involved in intermolecular hydrogen bonds, and may 
therefore not be freely accessible for ionization. Increasing the pH, the particles surface 
potential becomes negatively charged and exhibits a constant, slightly negative potential value 
of approximately -17.4 ± 1.6 mV at pH 6.5 and higher. Below pH 5.5 the Zeta potential changes 
to positive values of +8.4 mV at pH 5.0 and +16.8 mV at pH 4.0. 
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Figure 38: Influence of pH on Zeta potential of suspensions with 15 mg/mL API in WfI. Error bars represent 
standard deviations from triplicate measurements. 
 
In summary, the observed viscosity results are in line with the expectations from Zeta potential 
measurements. The higher viscosity as detected around the IEP correlates with a lack of 
electrostatic repulsive forces and hence strongest interparticulate interaction. Considering the 
calculated yield points fitted by the Casson model, the results are comparable high (Figure 39, 
correlation coefficients between 0.8967 at pH 4 and 0.9772 at pH 7.5). 
 
Figure 39: Influence of pH on yield point (calculated by the Casson model) of suspensions with 300 mg/mL 
API in WfI. Error bars represent standard deviations from triplicate measurements. 
 
The thixotropic behavior as the hysteresis area between the curves of the up and the down 
shearing is shown in Figure 40. The hysteresis area varies less at pH 7 and higher, but there 
is no effect of pH on thixotropy. In conclusion, the variation of the pH influences the viscosity 
of the suspension, but not to a sufficient extent to enable syringeability of the formulation. 
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Figure 40: Influence of pH on hysteresis area of the rheometric analysis of suspensions with 300 mg/mL 
API in WfI. Error bars represent standard deviations from triplicate measurements. 
Additionally, the viscosity of less concentrated suspension with 30, 100 and 200 mg/mL API at 
pH 4, 5.5, 7 and 9 is determined (Figure 41). The viscosity differences dependent on pH are 
small at all concentrations. Suspensions at pH 7 and pH 9 tend to be less viscous compared 
to pH 5.5. Further decrease to pH 4 does not change the viscosity. There is also no effect 
dependent on concentration. 
 
 
Figure 41: Influence of pH on viscosity of suspension with 30 mg/mL (black bars), 100 mg/mL (white bars) 
and 300 mg/mL (grey bars) API at ẙ = 0.2 1/s (A) and ẙ = 12.6 1/s (B). Error bars represent standard deviations 
from triplicate measurements. 
 
Overall, it can concluded that the viscosity is only slightly affected by the pH. The viscosity 
does not generally decrease with increasing Zeta potential. 
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6.1.2 Influence of ions on viscosity of 300 mg/mL API suspension 
The addition of ions may lower the viscosity by reducing the effective volume fraction of the 
dispersed phase due to a compressed double layer and by affecting the repulsive forces. 
These effects are dependent on the ion concentration. The influence of NaCl (50 mM, 100 mM, 
150 mM) and 150 mM KCl on the viscosity of suspensions with 300 mg/mL API at pH 7 is 
determined. CaCl2 was not further analyzed as no effect was seen in preliminary tests. Beside 
the addition of ions, also glucose with a concentration of 300 mM was tested for a viscosity 
decrease. Li et al. [81] found a viscosity decrease of nanometric alumina suspensions due to 
the addition of fructose. This was attributed to the adsorption of fructose on the particle surface 
and water displacement. Thus, the bulk water is increased and the viscosity becomes lower. 
Also several other monosaccharides are able to reduce the viscosity of different dispersed 
systems [82, 83]. 
Figure 42 shows the effect of salt and glucose addition on viscosity as a function of the shear 
rate. The viscosity of the 300 mg/mL API suspensions containing ions or glucose is 
independent from the ion concentration or the addition of monosaccharide. Regarding the 
viscosity values at low shear rates (ẙ = 0.2 and ẙ = 12.6 1/s), there is also no noticeable 
difference (Figure 43). The thixotropic behavior of the suspensions is shown in Figure 44. The 
suspensions with 150 mM NaCl and 300 mM glucose tend to a slightly less thixotropic behavior 
than the samples without ions and with 150 mM KCl but the differences are insignificant. 
In all cases, the paste-like character of the suspension remains unchanged and the 
suspensions are too viscous for the withdrawal out of the vial. 
 
Figure 42: Influence of ions and glucose on viscosity of suspension with 300 mg/mL API (pH 7). Error bars 
represent standard deviations from triplicate measurements. 
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Figure 43: Influence of ions and glucose on viscosity of suspension with 300 mg/mL API (pH 7) at ẙ = 0.2 1/s 
(A) and ẙ = 12.6 1/s (B). Error bars represent standard deviations from triplicate measurements. 
 
 
Figure 44: Influence of ions and glucose on thixotropic behavior of suspension with 300 mg/mL API (pH 7). 
Error bars represent standard deviations from triplicate measurements. 
 
 
6.1.3 Effect of particle size on viscosity of 300 mg/mL API suspension 
The particle size can influence the viscosity of concentrated suspensions. More viscous 
systems are expected with small particle sizes due to an increase in the effective volume of 
the dispersed phase and interparticulate contact density [28]. Consequently, the viscosity of 
suspensions containing 300 mg/mL API of different particle size is analyzed (Figure 45). The 
smallest particles D(0.05) of all suspensions are comparable in size. The non-micronized 
suspensions stirred for 48 hours offer larger particles than the micronized ones indicated by 
the higher values for D(0.10), D(0.50), D(0.90) and D(0.95). The suspensions with additionally 
milled micronized raw material (1 mm beads, 10 min) contain the smallest particles with a 
D(0.95) of 22.85 µm. 
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Figure 45: Particle size distribution of suspensions with 300 mg/mL non-micronized API (■), 300 mg/mL 
micronized API (▲) and 300 mg/mL micronized API additionally milled (●) used for viscosity determination. 
Error bars represent standard deviations from triplicate measurements. 
 
The viscosity values of the different suspensions are presented in Figure 46. It can be 
demonstrated that the particle size has a significant influence on the viscosity. A decrease in 
particle size leads to significantly higher viscosity values of the suspensions. At ẙ = 0.2 1/s the 
viscosity of the suspensions with small and medium particle sizes does not differ significantly. 
At ẙ = 12.6 1/s there is a significant difference between all particle sizes. 
 
  
Figure 46: Viscosity of suspensions with 300 mg/mL non-micronized API (black), 300 mg/mL micronized 
API (white) and 300 mg/mL micronized API additionally milled (grey) at ẙ = 0.2 1/s and ẙ = 12.6 1/s. Error 
bars represent standard deviations from triplicate measurements. 
 
However, a decrease in suspension viscosity by using large particles appears not to be 
suitable. Despite a D(0.95) value of about 40 µm, needle shaped particles longer than 120 µm 
are detected by microscopy. These particles may block the 25 Gauge needle and would need 
to be completely rouled out. 
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6.1.4 Effect of phospholipids on suspension viscosity 
Dimyristoylphosphoglycerol (DMPG) 
For further formulation development, different excipients are tested with the objective to reduce 
the viscosity at low shear rates and to improve syringeability. From literature it is known that 
surfactants can reduce the viscosity by introducing steric or static repulsive forces [61, 62, 64] 
and by reducing particle interaction [24, 48]. Therefore, different phospholipids are chosen, 
mainly dimyristoylphosphoglycerol (DMPG), as well as the commonly used polysorbate 80 
(PS 80) and mixtures containing polysorbate 80 and sorbitan monooleate (SO). The possible 
interaction of DMPG with Cilengitide is studied in more detail to get an understanding of the 
mechanisms of viscosity reduction. 
 
First experiments at shear rates of 100 1/s and higher show a viscosity reduction of 
suspensions containing DMPG (Figure 47). The most pronounced reduction is achieved by the 
addition of 2 mg/mL DMPG which was hence selected as phospholipid concentration for further 
development. DMPG alone dispersed in water leads to a marginal viscosity increase (Figure 
48). 
 
 
Figure 47: Viscosity of suspensions with 300 mg/mL API (■) and with 1 mg/mL (●), 2 mg/mL (▲) and 
5 mg/mL (○) DMPG. 
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Figure 48: Viscosity of DMPG dispersions as a function of the concentration (without API). 
 
Whether the higher viscosity in water for the 5 mg/mL DMPG dispersion is related to the higher 
viscosity of the API suspension is unclear. The fact that the beneficial effect of 1 mg/mL DMPG 
on suspension viscosity is less might be explained by an incomplete surface coverage. 1 mg 
DMPG (8.75*1017 molecules) theoretically cover 1.05 m2, assuming that one DMPG molecule 
occupies an area of 1.2 nm2 [84]. The surface area of 300 mg Cilengitide is approximately 
1.06 m2 determined by gas adsorption method. 
 
The viscosity of the DMPG-containing suspension compared to the aqueous suspension at 
low shear rates of 0 - 100 1/s is shown in Figure 49. Suspensions with DMPG are remarkably 
reduced in viscosity in the low shear rate range. At ẙ = 0.2 1/s the suspension in WfI exhibits 
48.1 Pas with high variability (SD = 40 Pas, n = 3) whereas the 2 mg/mL DMPG containing 
system features 7.7 ± 0.7 Pas. 
 
 
Figure 49: Viscosity of 300 mg/mL Cilengitide in WfI (■) and with 2 mg/mL DMPG added (▲) at pH 7. Error 
bars represent standard deviations from triplicate measurements. 
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Fitting the curves to the Casson model gives an average yield point of 4.9 ± 2.4 Pa (r = 0.9640) 
for the 2 mg/mL DMPG suspensions compared to 9.9 ± 1.9 Pa (r = 0.9681) for the WFI 
suspension. The thixotropic behavior is not changed with the addition of 2 mg/mL DMPG 
(1918.7 ± 207.6 Pa/s for suspension in WFI, 2277.0 ± 380.6 Pa/s for suspension with 
2 mg/mL DMPG). 
It can be concluded that the addition of the DMPG strongly impacts the viscosity. The viscosity 
reduction is most pronounced with 2 mg/mL DMPG. The suspensions exhibit a lower yield 
point and the flow behavior of the different samples is less variable when compared to a 
suspension in WfI. With addition of 2 mg/mL DMPG the suspension becomes syringeable as 
it is possible to extract 1.0 mL from the vial within 17 ± 1 s using a 25 G needle (discussed in 
Chapter 6.2.5, Figure 83). 
 
 
Characterization of the DMPG structure in presence of Cilengitide 
From literature it is known that DMPG may build a variety of lamellar structures in water. The 
size and shape of the bilayers depend on the pH and the ionic strength of the dispersion, the 
kind of added ions, the temperature and the storage time. Aqueous dispersions of DMPG form 
polyanionic unilamellar vesicles [85] or bilayer fragments and bilayered micelles (bicelles) [86]. 
Fernandez [87] observed submicroscopic vesicles in presence of up to 20 mM NaCl. With 
50 mM NaCl most molecules are arranged in small vesicles and giant (loose) multilamellar 
vesicles (MLVs) start to appear [87]. A further increase of the ionic strength leads to denser 
and more MLVs. MLVs are the prevailing structures when 500 mM NaCl is added. Giant DMPG 
vesicles were found in 10 mM Hepes buffer at pH 7.4 with 2 mM NaCl at different temperatures 
by Riske et al. [88]. Epand [89] showed that flat sheets exist for aged DMPG at low 
temperature. At 50 °C, the lipid spontaneously vesiculates. The vesicle size is not uniform but 
they are generally larger (100-300 nm) than some of the vesicles and fragments formed at low 
ionic strength (20-30 nm, Epand and Hui, [90]). Spinozzi et al. [91] confirm the existence of 
pores in DMPG bilayers at higher DMPG concentrations (300 mM) which were already 
proposed for 70 mM DMPG in water [92]. Leaky DMPG vesicles were found by Barroso [93] 
at low ionic strength (10 mM Hepes buffer). The structural changes of DMPG dispersed in 
water during storage were investigated by Garidel [94]. Besides small vesicles, flat or slightly 
curved multilayered lamellae or cochleate cylinders are found at low temperatures (4 °C). The 
film expanded when the NaCl amount is increased caused by ionization of the DMPG 
headgroup. A more condensed film is achieved with increasing the NaCl concentration and 
lowering the pH-value due to the reduction of the electrostatic repulsion and the possibility for 
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the formation of a hydrogen bonding network. Beside electrostatic effects, site-specific binding 
was found for Ca2+, Mg2+ and Sr2+. 
Consequently, DMPG structures are analyzed when dispersed in water in presence of 
dissolved Cilengitide, NaCl or glucose. Turbidity measurements are performed to detect 
structural changes when other components are added to the DMPG dispersion. Cryo-TEM 
micrographs and DLS measurements are taken to show whether bilayer structures are built. If 
they are consistent in presence of API and NaCl, the viscosity reduction may be caused by the 
bilayer structures acting as a kind of ball bearing between suspended API particles. More 
information about the potential interaction should be received from NMR spectroscopy. Ionic 
interaction may take place between the negatively charged headgroup of the DMPG and the 
positively charged arginine of the Cilengitide molecule. Furthermore, the hydrophobic carbon 
chain of the phospholipid may interact with the hydrophobic amino acids phenylalanine and 
valine. The mentioned analytical methods only enable the characterization of the DMPG 
structures in presence of dissolved API. Interaction between DMPG and suspended API 
particles are characterized with Zeta potential measurements. 
 
 
Turbidity and dynamic light scattering measurement of DMPG dispersions 
Changes in turbidity and size indicate a potential interaction between dissolved Cilengitide and 
DMPG. Therefore, samples containing 2 mg/mL DMPG are characterized and compared to 
samples with 4 mg/mL API, 150 mM NaCl or 300 mM glucose added (pH 7). The turbidity of 
2 mg/mL DMPG in water is low (2.1 ± 0.2 NTU) and even less in presence of API 
(0.7 ± 0.0 NTU). DLS measurements show that DMPG dispersed in water exhibits an average 
structure size of 37 nm with the built structures being quite polydisperse as indicated by a high 
polydispersity index (PDI) of 0.7. The samples with API added are too polydisperse to provide 
a useful average size. The turbidity is higher and the difference more pronounced for NaCl 
containing DMPG dispersions. Samples with 2 mg/mL DMPG and 150 mM NaCl exhibit 
127.3 ± 4.0 NTU and 6.0 ± 0.1 NTU with 4 mg/mL API added. Much larger structures are 
detected in presence of 150 mM NaCl but without API (140 nm, PDI = 0.17) in contrast to 
samples with Cilengitide (30 nm, PDI = 0.5). The addition of NaCl induces ionization of the 
headgroup of DMPG causing expansion of the bilayer structures [84]. In contrast, the turbidity 
and DLS results seen for samples with 300 mM glucose are comparable to the samples without 
an isotonic agent. The turbidity is low for samples with 300 mM glucose (2.1 ± 0.2 NTU) and 
further reduced with 4 mg/mL API added (0.5 ± 0.0 NTU). Structures in the size range of 42 nm 
and with a PDI of 0.6 are detected without API. The result for the API containing sample are 
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not useable as they are too polydisperse. In conclusion, the observed changes in turbidity and 
size point towards potential interaction of DMPG with Cilengitide. 
 
 
Cryo-TEM images of DMPG dispersions 
Cryo-TEM is used to characterize the structures which DMPG builds. DMPG dispersed in water 
forms bilayered micelles (bicelles or disc micelles) as shown in Figure 50A with a size of around 
40 nm diameter. This is in line with the DLS results and literature [86]. In presence of 4 mg/mL 
API dissolved in water the bicelles are destroyed and spherical micelles are formed (Figure 
50 B), which are more variable in size (between 25 to 75 nm). 
 
 
Figure 50: Cryo-TEM pictures of 2 mg/mL DMPG dispersed in water (A) and 4 mg/mL API solution (B). 
 
The corresponding 150 mM NaCl containing samples exhibit larger, spherical vesicles (Figure 
51). With 4 mg/mL API the vesicles are again destroyed and irregularly formed micelles are 
detected. This micellization of phospholipid bilayers was also observed for surface-active 
peptides like melittin [95, 96]. 
A B 
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Figure 51: Cryo-TEM pictures of 2 mg/mL DMPG with 150 mM NaCl dispersed in water (A) and 4 mg/mL API 
solution (B). 
 
Thus, the DMPG-bicelles are not preserved when Cilengitide is added and viscosity reduction 
by DMPG structures acting as ball bearing is less likely. 
 
 
NMR-spectroscopy characterizing the interaction between DMPG and Cilengitide 
To get a better understanding on the interaction mechanism between dissolved Cilengitide and 
DMPG molecules, the supernatant of suspensions containing 300 mg/mL API and 2 mg/mL 
DMPG was investigated by NMR-spectroscopy. The 1H-NMR stacked plot of the supernatant 
of Cilengitide suspension (300 mg/mL) and the Cilengitide/DMPG suspension (300 mg/mL 
API + 2 mg/mL DMPG) in D2O at pH 6.4 is shown in Figure 52. For the signals marked in red 
squares, there is no signal overlap of resonances of DMPG with that of Cilengitide allowing the 
differentiation between inter- and intramolecular interaction. However, the non-overlapping 
regions belong to hydrophobic groups. The ionic interaction between the negatively charged 
phosphate group and the positive arginine cannot be detected due to the overlap of the 
phosphate group signal with the arginine signal of Cilengitide at around 4 ppm. 
A B 
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Figure 52: Stacked plot of 4 mg/mL Cilengitide dissolved in D2O (below) and 2 mg/mL DMPG (above). The 
letters in the spectra indicate DMPG and Cilengitide resonances assigned to the chemical group in the 
formula. Group C 1 of Cilengitide is not observable due to water suppression. No spectral overlap of 
Cilengitide and DMPG is indicated by the red boxes. 
 
In order to probe for intermolecular interactions, a 2D NOESY (Nuclear Overhauser Effect 
Spectroscopy) NMR spectrum of the supernatant of Cilengitide suspension (300 mg/mL) 
containing 2 mg/mL DMPG in D2O was recorded (Figure 53, pH 6.4). The NOESY NMR 
spectrum allows one to identify spatially proximate groups. If there is a pronounced interaction 
of DMPG with Cilengitide, the interacting groups will be necessarily close in space to each 
other and hence give a correlation in a 2D- NOESY NMR spectrum. In Figure 53 unambiguous 
DMPG/Cilengitide correlations can be seen for the CH2-group of the myristoyl side chain at 
1.3 ppm with both the valine and phenylalanine group of Cilengitide. From this finding a strong 
hydrophobic interaction can be deduced. The other signals outside the diagonal correspond to 
intramolecular interactions. 
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Figure 53: 2D NOESY NMR spectrum of the supernatant of Cilengitide suspension (300 mg/mL) containing 
DMPG (2 mg/mL) at pH 6.4. All signals outside the diagonal correspond to spatially close 1H-nuclei. 
 
To get information about the dependency of the observed DMPG / Cilengitide interactions upon 
molecular charge, 2D NOESY NMR spectra were also recorded for the supernatants of 
samples with pH 4.2, 5.4 and 6.9 (pD 4.6, 5.8, 7.3) (Figure 54 A-C). In all spectra, the same 
correlations between the hydrophobic part of DMPG and the phenylalanine and valine groups 
of Cilengitide as seen in the supernatant of suspension at pH 6.4 are observed, leading to the 
conclusion that hydrophobic interactions between DMPG and Cilengitide in solution occur at 
all pH values. 
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Figure 54: 2D NOESY NMR spectrum of the supernatant of Cilengitide suspension (300 mg/mL) containing 
DMPG (2 mg/mL) at pH 6.9 (A), pH 5.4 (B) and pH 4.2 (C). All signals outside the diagonal correspond to 
spatially close 1H-nuclei. 
 
B 
A 
C 
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The results of NMR spectroscopy confirm hydrophobic interaction between the myristoyl side 
chain of DMPG and phenylalanine and valine of the Cilengitide molecule in solution at all pH 
values leading to the destruction of bilayer structures seen in Cryo-TEM pictures. However, 
electrostatic interaction is not proven as the signal for the phosphate group does overlap of the 
Cilengitde signals. 
 
 
6.1.5 Effect of varying pH on viscosity of 300 mg/mL Cilengitide suspensions 
containing 2 mg/mL DMPG 
Beside the addition of DMPG, the pH of DMPG containing Cilengtide suspension is varied and 
the effect on viscosity is studied. A remarkably low viscosity is found at pH 5 and 5.5 over the 
whole shear range (Figure 55). 
 
 
Figure 55: Viscosity of suspensions containing 300 mg/mL API and 2 mg/mL DMPG as a function of pH. 
Error bars represent standard deviations from triplicate measurements. 
 
Figure 56 shows the viscosity values at the low shear rate of ẙ = 0.2 1/s relevant for flow in the 
vial. Besides the suspensions with pH 5 and 5.5, the suspensions at pH 6 also exhibit a minimal 
viscosity of less than at 1.2 Pas at this shear rate. At ẙ = 12.6 1/s a significantly lower viscosity 
is found for suspensions with pH 5 and 5.5 as compared to suspensions with other pH value 
(Figure 57). Further increase in the shear rate leads to a constant viscosity of 30 mPas at pH 6 
or approximately 4 mPas at pH 5 and 5.5, respectively. 
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Figure 56: Viscosity of suspensions containing 300 mg/mL API and 2 mg/mL DMPG as a function of pH at 
ẙ = 0.2 1/s. Error bars represent standard deviations from triplicate measurements. 
 
Figure 57: Viscosity of suspensions containing 300 mg/mL API and 2 mg/mL DMPG as a function of pH at 
ẙ = 12.6 1/s. Error bars represent standard deviations from triplicate measurements. 
 
Yield points are generally high for all pH values but suspensions at pH 6 tend to offer a lower 
yield point (Figure 58). The fitting cannot be performed for pH 5 and 5.5 as these suspensions 
of low viscosity exhibit not yield point (calculated value is 0). 
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Figure 58: Influence of pH on yield point (calculated by the Casson model) of suspensions with 300 mg/mL 
API and 2 mg/mL DMPG as a function of pH. Error bars represent standard deviations from triplicate 
measurements. 
 
When comparing the viscosity results to suspensions in WfI only it can be noted that the 
viscosity is strongly reduced over the whole pH-range when the phospholipid is added (Figure 
59, Figure 60). At pH 5.5, the viscosity of suspensions in WFI tends to be the highest, whereas 
suspensions with DMPG display a viscosity minimum at this pH. 
 
Figure 59: Viscosity of suspensions with 300 mg/mL API (black) and 2 mg/mL DMPG (white) compared to 
300 mg/mL suspensions in WfI as a function of pH (ẙ = 0.2 1/s). Error bars represent standard deviations 
from triplicate measurements. 
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Figure 60: Viscosity of suspensions with 300 mg/mL API (black) and 2 mg/mL DMPG (white) compared to 
300 mg/mL suspensions in WfI as a function of pH (ẙ = 12.6 1/s). Error bars represent standard deviations 
from triplicate measurements. 
 
These low viscous DMPG suspensions at pH 5 - 6 show a very low sediment volume compared 
to the suspensions at higher pH (Figure 61) with a sedimentation degree F of 0.55 at pH 5.5 
compared to 0.99 at pH 7. 
 
Figure 61: Sediment of suspensions containing 300 mg/mL API and 2 mg/mL DMPG at pH 5.5 (left) and pH 7 
(right) after 4 hours. 
 
The micrographs of suspended particles at the lower pH value show seperated, individual 
particles, while suspensions at pH 7 contain agglomerates indicating a flocculated system 
(Figure 62). 
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Figure 62: Microscopic pictures of suspensions containing 300 mg/mL API and 2 mg/mL DMPG at pH 5.5 
(A) and pH 7 (B) after 1:10 dilution. Bar corresponds to 200 µm. 
 
This result gives rise to the conclusion that the suspensions at pH 5.5 are deflocculated 
systems that are characterized by non-agglomerated particles which usually settle more slowly 
compared to flocculated particles. Nevertheless, the sedimentation velocity depends on the 
particle size and concentration. In case for suspensions at pH 7 particles agglomerate and 
built an inner, scaffold-like structure leading to a complete hindrance of sedimentation and high 
viscosity in combination with the high concentration. In case for suspensions at pH 5.5 no inner 
structure is built and thus, particles settle. 
 
The corresponding Zeta potential results of suspensions containing 15 mg/mL API and 
2 mg/mL DMPG dependent on pH are shown in Figure 63 in comparison to the suspensions 
in WfI and 2 mg/mL DMPG dispersions. The Cilengitide concentration was limited to 15 mg/mL 
as higher concentrations did not show an evaluable signal. But comparable Zeta potential 
results are found for the low-concentrated suspension (-67.6 ± 1.5 mV) and saturated solution 
(-73.4 ± 7.6 mV) at pH 6 indicating that similar interaction occurs for dissolved or suspended 
Cilengitide, respectively. 
 
 
200 µm 
 
200 µm 
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Figure 63: Zeta potential of 2 mg/mL DMPG dispersions (▲), suspensions with 15 mg/mL in WfI (■) and with 
2 mg/mL DMPG (●) as a function of pH. Error bars represent standard deviations from triplicate 
measurements. 
 
In the considered range, the Zeta potential of the DMPG-containing suspensions is always 
negative in contrast to the potential of suspensions in WfI. There is a Zeta potential maximum 
observed at pH 5 - 6, the same pH range the 300 mg/mL in which suspensions exhibit the 
lowest viscosity and the Cilengitide suspended in water exhibit its isoelectric point (pH 5.5). 
The Zeta potential at this maximum is even higher than the Zeta potential of the dispersed 
DMPG vesicles at this pH. Above pH 6.5, the Zeta potential of suspensions with 2 mg/mL 
DMPG increases and becomes less negative, whereas suspensions in WfI show a constant 
potential. The DMPG vesicles exhibit a more or less constant potential from pH 4 to 6.5. Above 
pH 6.5, they tend to become more negatively charged and the observed potential becomes 
even more negative than the API particles suspended in 2 mg/mL DMPG. At pH 6.5, the 
suspended particles and the DMPG vesicles exhibit a similar potential. 
 
To observe the effect of the DMPG concentration on the Zeta potential as well as to confirm 
the interaction between the Cilengitide and the phospholipid, the DMPG concentration is varied 
(Figure 64) and later on, the supernatant of the samples is replaced by saturated API solution 
(Figure 65). The results for suspensions show a comparable Zeta potential for different DMPG 
concentrations between 0.05 and 2 mg/mL. A difference dependent on the DMPG amount is 
detected at pH 6, where the Zeta potential becomes less negative with decreasing amount of 
DMPG. The constant Zeta potential shows that the maximum amount of DMPG is attached to 
the particles by adding 0.05 mg/mL of the phospholipid. In contrast, the absolute value of the 
Zeta potential of the suspended particles with 0.01 mg/mL DMPG is lower in a wide pH range 
of 4 – 7 leading to the conclusion that the particle surface is not completely covered with DMPG 
molecules. However, the Zeta potential is constant for all suspensions with 0.01 to 2 mg/mL 
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DMPG added at pH 7.5 – 9 suggesting that the maximum interaction potential of DMPG with 
negatively charged Cilengitide particles is less and is already reached with the lowest DMPG 
concentration. 
 
 
Figure 64: Zeta potential of suspensions with 15 mg/mL API and 0.01 mg/mL (■), 0.05 mg/mL (▲), 
0.1 mg/mL (●) and 2 mg/mL (○) DMPG as a function of pH. Error bars represent standard deviations from 
triplicate measurements. 
 
The Zeta potential becomes less negative when the supernatant is replaced (Figure 65). At 
pH 4 and above 7 the Zeta potential is constant after the first replacement. In the range of pH 5 
to 6.5 the Zeta potential further decreases with the second replacement indicating that loosely 
bound or unbound DMPG molecules are present. In general, this result confirms that API 
particles are detected and not DMPG structures. 
 
Figure 65: Zeta potential of suspensions containing 15 mg/mL API (■) and with supernatant replaced 
once (▲) and twice (●) as a function of pH. Error bars represent standard deviations from triplicate 
measurements. 
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The Zeta potential results of suspensions containing DMPG in different concentrations and 
with replaced supernatants lead to the conclusion that the interaction between DMPG and 
Cilengitide depend on the pH of the suspensions. The most pronounced interaction seems to 
occur around the isoelectric point (pH 5 - 6), where the pure Cilengitide particles suspended in 
water are overall uncharged but exhibit a highly negative potential in suspensions with DMPG. 
The extent of interaction seems to be less at pH values above pH 6.5 and at pH 4 compared 
to pH 5 - 6. At pH 4, the absolute value of Zeta potential is generally the lowest. Additionally, 
suspensions at pH 4 and 6 show a concentration dependent Zeta potential. The potential is 
constant for suspensions from pH 7 - 9 and almost independent from the amount of DMPG 
added. The supernatant replacement steps lower the potential value, but only marginally. 
Zeta potential measurements of 15 mg/mL Cilengitide suspensions with 150 mM NaCl added 
show a shift of the isoelectric point of Cilengitide particles to approximately pH 4 (Figure 66). 
The NaCl-containing suspensions with 2 mg/mL DMPG offer deflocculation at pH 4 confirming 
the stronger interaction between DMPG and API around the isoelectric point as shown for 
suspensions without NaCl. However, the suspensions with 15 mg/mL Cilengitide, 2 mg/mL 
DMPG and 150 mM NaCl do not show a Zeta potential maximum. The Zeta potential remains 
fairly constant at around -40 mV for pH 5.5 to pH 9 and decreases to -36 mV at pH 5 or -24 mV 
at pH 4, respectively. The addition of 150 mM NaCl seems to quench the Zeta potential 
differences due to the strong compression of the double layer. 
 
Figure 66: Zetapotential of suspensions with 15 mg/mL API in WfI (■), with 9 mg/mL NaCl (▲), 2 mg/mL 
DMPG (○) and with 2 mg/mL DMPG and 9 mg/mL NaCl (●). Error bars represent standard deviations from 
triplicate measurements. 
 
In summary, turbidity, DLS, Cryo-TEM and NMR analysis results confirm the interactions 
between dissolved Cilengitide and DMPG molecules. The addition of Cilengitide to the DMPG 
dispersion leads to the destruction of bilayer structures seen in Cryo-TEM pictures due to 
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interactions with Cilengitide as demonstrated by NMR. Electrostatic interactions between the 
negatively charged phosphate groups and the positively charged Cilengitide particles at pH 4 
could not be detected due to the overlap of the phosphate group signal with the Cilengitide 
arginine signal around 4 ppm. Interaction between suspended Cilengitide particles and 
dispersed DMPG molecules are confirmed by Zeta potential measurements. Most pronounced 
interaction between Cilengitide and DMPG is seen around the isoelectric point. Comparable 
Zeta potential results of the low-concentrated suspensions and the saturated solution 
(-73.4 ± 7.6 mV) indicate that observed interaction mechanisms in solution are also present for 
suspensions. 
 
 
6.1.6 Interaction model for Cilengitide and DMPG at varying pH values 
Based on the measured results an interaction model explaining the varying fluidity of 
suspensions at pH 4, 5.5 and 7 is conceived (Figure 67 a - c). The Cilengitide particles in water 
are positively charged at pH 4, in total neutral at pH 5.5 and negatively charged at pH 7. 
Generally, the hydrophobic amino acids are orientated outwardly as known from single-crystal 
structure analysis (see chapter 4.1). Furthermore, dissolved API has to be taken into account 
since more dissolved API molecules are in the environment of a solid particle than DMPG 
molecules (API solubility 6 mg/mL). 
At pH 4 (Figure 67 a), the Zeta potential of the Cilengitide particles is positive, whereas DMPG 
molecules are negatively charged (pKs ~ 3). In solution DMPG and Cilengitide interact leading 
to a negative Zeta potential by DMPG phosphate groups. Electrostatic interactions are also 
expected between the negatively charged phospholipid and positively charged protein. The 
dissolved API molecules may additionally interact with the negatively charged head group of 
DMPG as well as with the particle surface due to their surface-active properties (surface 
tension of a saturated API-solution 54.70 ± 1.38 mN/m). Agglomerates as observed by 
microscopy are due to physical particle interaction. The absolute value of the Zeta potential is 
lower compared to other pH-values, leading to the conclusion that the surface of the particle 
is not fully covered with negative DMPG molecules. Thus, the particles are enabled to network 
which causes the higher viscosity compared to pH 5.5. 
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Figure 67 a: Interaction model at pH 4 demonstrating the interaction between a suspended API particle 
(  ) with its hydrophobic sides (  ), DMPG (  ) and dissolved API molecules (  ). 
 
Figure 67 b shows the interactions model at pH 5.5 at which the API particles exhibit their 
isoelectric point in water. The hydrophobic interaction between the DMPG molecules and the 
net uncharged particle surface is strongest while electrostatic interaction between particle 
surface and DMPG is at a minimum. A very close packing of the DMPG molecules on the 
particle surface is enabled by the dissolved, zwitter-ionic API molecules which reduce the 
electrostatic repulsion between the negatively charged head groups of DMPG. Thus, a highly 
negative Zeta potential results. The high surface coverage with negatively charges molecules 
leads to separated suspended particles with minimal interparticle interaction and without 
agglomeration (see micrograph, Figure 67 b). This absence of a particle network leads to a 
low suspension viscosity. The separated particles sediment quite fast and build a closely 
packed sediment which has a high caking potential. Usually, deflocculated systems exhibit a 
slow sedimentation rate due to the smaller size of separated particles. In this case, the 
separated particles are large enough for a fast sedimentation. Additionally, due to the 
sedimentation the stabilizing potential barrier (repulsive forces) is overcome and a compact, 
hardly redispersable sediment is built. 
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Figure 67 b: Interaction model at pH 5.5 demonstrating the interaction between a suspended API particle 
(  ) with its hydrophobic sides (  ), DMPG (  ) and dissolved API molecules (  ). 
 
The zeta potential of particles at pH 7 is negative resulting in repulsive forces between 
suspended API and the negatively charged phospholipid (Figure 67 c). Nevertheless, some 
DMPG molecules are attached via hydrophobic interactions on the particle surface and 
potentially localized charge interaction, leading to a higher absolute zeta potential than pure 
API. Nevertheless, due to incomplete surface coverage, particles interact with each other and 
agglomerates are built. A flocculated structure is observed. This result in a higher viscosity of 
suspensions at pH 7 compared to pH 5.5. 
 
 
Figure 67 c: Interaction model at pH 7 demonstrating the interaction between a suspended API particle 
(  ) with its hydrophobic sides (  ), DMPG (  ) and dissolved API molecules (  ). 
 
Overall, the viscosity at different pH-values correlates with the varying adsorbed amount of 
DMPG on the particle surface. A higher surface coverage increases electrostatic repulsions 
and decreases the interparticle attraction which have a significant impact at high 
concentrations. 
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6.1.7  Addition of phospholipids with alternative chain length to confirm the interaction 
model 
In order to confirm the interaction model, DMPG is replaced by other phospholipids which differ 
in the length of the fatty acid moiety (C10: Didecanoylphosphoglycerol (DDPG), 
C12: Dilauroylphosphoglycerol (DLPG), C16: Dipalmitoylphosphoglycerol (DPPG), 
C18: Distearoylphosphoglycerol (DSPG)). The interaction of the phospholipid with the 
Cilengitide particle may depend on the length of the fatty acid, meaning the hydrophobicity and 
the size of the phospholipid. On the one hand side, the more hydrophobic phospholipids might 
interact stronger with the Cilengitide particles resulting in a higher viscosity reduction as 
compared to hydrophilic phospholipids with short fatty acid chain length. On the other hand 
side, smaller phospholipids with shorter fatty acid moieties might cover the surface more 
densely, leading to a more pronounced charge based repulsion and higher viscosity reduction. 
It is reported that phosphoglycerols with fatty acids longer than C11 or C12 support bilayer 
structures in water [97]. Whereas phosphoglycerols with shorter fatty acids form micelles in 
water due to their geometric constraints [97]. The zeta potential of suspensions containing 
15 mg/mL API and 0.1 mg/mL phospholipids at pH 4, 5.5 and 7 as well as the viscosity of 
suspensions with 300 mg/mL API and 2 mg/mL phospholipid at the mentioned pH-values are 
determined. 
Figure 68 A shows the viscosity at ẙ = 0.2 1/s for suspensions containing the selected 
phospholipids at pH 4, 5.5 and 7. The viscosity of all suspensions is reduced at pH 5.5 
compared to the other pH-values. The respective samples show a higher absolute zeta 
potential (Figure 69), leading to the conclusion that the surface is more covered with 
phospholipid molecules and thus, the attractive interaction between the Cilengitide particles is 
reduced resulting in a lower viscosity. Considering the influence of the fatty acid chains on the 
viscosity, no continuous trend is observed (Figure 68 A, ẙ = 0.2 1/s). At pH 4, suspensions with 
the more hydrophilic DDPG and DLPG seem to have a significantly lower viscosity compared 
to the DMPG containing samples. The DPPG and DSPG containing samples show a similar 
viscosity as the DMPG formulation. At pH 5.5, the viscosity of the suspensions containing the 
alternative phospholipids is similar to the DMPG containing suspension except for DDPG. At 
pH 7 the DDPG or DLPG containing formulations seems to be less viscous than the DMPG, 
DPPG and DSPG containing formulations. However, it is seen that the measurement quality 
for DDPG and DLPG containing samples at pH 4 and 7 is possibly reduced leading to an 
apparently lower viscosity also indicated by a lower viscosity value detected during back 
shearing. At a shear rate of ẙ = 12.6 1/s all phospholipid containing formulations exhibit a 
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similar viscosity at pH 4 and 7 of approximately 0.2 Pas (Figure 68 B). At pH 5.5 the viscosity 
is significantly lower except for the formulation containing the phospholipid DPPG. 
 
 
Figure 68: Viscosity of suspensions with 300 mg/mL API and 2 mg/mL alternative phospholipids (DDPG, 
DLPG, DPPG, DSPG) at pH 4 (black), pH 5.5 (white) and pH 7 (grey) compared with DMPG containing 
suspension at ẙ = 0.2 1/s (A) and ẙ = 12.6 1/s (B). Error bars represent standard deviation from triplicate 
measurements. 
 
 
Figure 69: Zeta potential of suspensions with 15 mg/mL API and 2 mg/mL of alternative phospholipids 
(DDPG, DLPG, DPPG, DSPG) at pH 4 (black), pH 5.5 (white) and pH 7 (grey) compared with DMPG containing 
suspension. Error bars represent standard deviation from triplicate measurements. 
 
At a typical shear rate applied during injection with a 25 Gauge needle (ẙ = 1000 1/s) the 
samples with the alternative phospholipids tend to be more viscous at pH 7 than the DMPG 
containing samples (Figure 70). At pH 5.5, the above mentioned higher viscosity of the 
suspension with DDPG is found again. All the other samples show similar viscosity. At pH 4 
the suspension with DMPG tend to be less viscous than samples with the alternative 
phospholipids. 
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Figure 70: Viscosity of suspensions with 300 mg/mL API and 2 mg/mL of alternative phospholipids (DDPG, 
DLPG, DPPG, DSPG) at pH 4 (black), pH 5.5 (white) and pH 7 (grey) compared with DMPG containing 
suspension at ẙ = 1000 1/s. Error bars represent standard deviation from triplicate measurements. 
 
In summary the viscosity of all phospholipid containing suspensions is reduced at pH 5.5 
compared to pH 4 and 7, confirming the interaction model. However, these formulations are 
deflocculated systems with a high caking potential and thus, not suitable as final formulation. 
The viscosity of the suspensions does not depend on the added phospholipid. Only at the 
highest shear rate a lower viscosity is detected for suspensions containing DMPG. Finally, for 
stability studies suspensions with 2 mg/mL DMPG at pH 7 are evaluated (see chapter 6.2). 
 
 
6.1.8 Polysorbate 80 and sorbitan monooleate as alternative surfactants 
In addition to the phospholipids as viscosity reducing agent, more commonly used non-ionic 
surfactants are tested with respect to their influence on the viscosity of the highly concentrated 
suspension. Polysorbate 80 (PS 80) as well as sorbitan monooleate (SO) were selected as 
they are acceptable for parenteral use and a wide HLB range can be covered by using mixtures 
of both components at different ratios. PS 80 itself with a HLB value of 15 and mixtures which 
cover a HLB range between 11.8 and 7.5 were tested (Table 10). Pure SO with a HLB value 
of 4.3 could not be used as it cannot be dispersed in water due to its high hydrophobicity. 
Additionally, the concentration of the added mixtures is varied from 1 to 10 mg/mL. 
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50 50 9.7 
40 60 8.6 
30 70 7.5 
0 100 
4.3 
Not dispersible in water 
Table 10: HLB values of different mixture ratio of PS 80 / SO mixtures. 
 
Figure 71 shows the viscosity of suspensions containing 2 mg/mL PS 80/SO mixtures at 
ẙ = 0.2 1/s. The viscosity of the suspension in WfI is significantly higher than the viscosity of 
suspensions containing 2 mg/mL surfactant mixtures with a HLB of 11.8 (mixing ratio 70/30) 
and less. The addition of PS 80 only does not lower the viscosity significantly, possibly due to 
lower surface interaction and thus, higher particle interaction. This suspension is still too 
viscous to draw 1 mL out of the vial within 20 s. The suspensions containing different ratios 
show similar viscosity and are comparable viscous to DMPG containing suspensions. 
 
 
Figure 71: Viscosity of suspensions with 300 mg/mL API and 2 mg/mL PS 80/SO mixtures compared to WfI 
and 2 mg/mL DMPG at ẙ = 0.2 1/s and pH 7. Error bars represent standard deviation from triplicate 
measurements. 
 
The Zeta potential of Cilengitide particles is not affected by the addition of the non-ionic 
surfactant mixtures (Figure 72). Suspensions containing 15 mg/mL Cilengitide and 2 mg/mL 
PS 80/O mixtures show an absolute value of approximately -19.2 ± 2.4 mV compared 
to -16.3 ± 1.4 mV for 15 mg/mL Cilengitide in WfI. A significantly higher potential is seen for 
suspensions with 0.1 mg/mL DMPG (-44.8 ± 6.4 mV). 
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Figure 72: Zeta potential of suspensions with 15 mg/mL API and 2 mg/mL PS 80/SO mixtures compared to 
WfI and 0.1 mg/mL DMPG at pH 7. Error bars represent standard deviation from triplicate measurements. 
 
The effect of surfactant concentrations on the viscosity of the suspension is shown in Figure 
73 at the lowest shear rate (ẙ = 0.2 1/s). The viscosity of suspensions with pure PS 80 depends 
on the concentration and lower values result with 5 mg/mL PS 80 or more. Nevertheless, the 
results vary widely and differ not significantly. The viscosity of the suspensions with 70/30 and 
60/40 mixtures do not depend on concentration. Suspensions with 50/50 mixtures tend to be 
less viscous with increasing surfactant concentrations. Considering the more lipophilic 
mixtures (40/60 and 30/70) the suspensions with 7.5 or 10 mg/mL are more viscous than 
suspensions with lower concentrations. This might be an effect of the higher viscosity of the 
surfactant dispersion itself. Figure 74 shows the viscosity of the placebo surfactant mixtures 
(without API). It is seen that the viscosity of the two most lipophilic mixtures at the highest 
concentrations (7.5 and 10 mg/mL) is markedly higher compared the other. 
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Figure 73: Viscosity of 300 mg/mL API suspensions as a function of mixing ratio and surfactant 
concentration compared to WfI and 2 mg/mL DMPG at ẙ = 0.2 1/s (pH 7). Error bars represent standard 
deviation from triplicate measurements. 
 
 
Figure 74: Viscosity of surfactant dispersions (without API) as a function of mixing ratio and surfactant 
concentration at ẙ = 0.2 1/s (pH 7). Error bars represent standard deviation from triplicate measurements. 
 
At medium shear rates no significant differences between DMPG and PS 80/SO mixtures are 
observed while the aqueous suspension is more viscous. Suspensions with PS 80 only tend 
to be more viscous than suspensions with SO included, but the differences are not significant. 
At this medium shear rate, the viscosity is a complex function of solid and liquid properties [40] 
so that the observed differences at lower shear rates obviously level off. 
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Figure 75: Viscosity of 300 mg/mL API suspensions as a function of mixing ratio and surfactant 
concentration compared to WfI and 2 mg/mL DMPG at ẙ = 12.6 1/s (pH 7). Error bars represent standard 
deviation from triplicate measurements. 
 
At the high shear rate ẙ = 1000 1/s only suspensions with PS 80/SO mixtures 40/60 and 30/70 
at 5 and 10 mg/mL concentrations yield lower viscosity values than the WfI samples. The 
viscosity of all the other suspensions is comparable to the WfI and DMPG suspensions. An 
influence of surfactant concentration is seen for suspensions with 50/50, 40/60 and 30/70 
mixtures. Nevertheless, all of the formulations are suitable with respect to the syringeability as 
even the WfI suspension can be injected with a 25 Gauge needle. 
 
 
Figure 76: Viscosity of 300 mg/mL API suspensions as a function of mixing ratio and surfactant 
concentration compared to WfI and 2 mg/mL DMPG at ẙ = 1000 1/s (pH 7). Error bars represent standard 
deviation from triplicate measurements. 
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These results lead to the conclusion that the addition of varying amounts of PS 80 does not 
lower the viscosity sufficiently due to insufficient particle surface interaction. Suspensions with 
mixtures exhibiting a HLB 11.8 and lower are considerably less viscous in the low shear range 
than the WfI and PS 80 samples. No obvious dependency on the HLB value and the added 
amount can be detected at the lowest shear rate. At the highest shear rate, lower viscosities 
were observed for suspensions with higher concentrated hydrophobic surfactant mixtures. In 
conclusion, 5 mg/mL PS 80/SO 40/60 is chosen for further investigations due to the viscosity-
reducing efficiency at mainly lower, but also higher shear rates. 
 
 
6.1.9 Influence of pH on viscosity of suspensions containing 2 mg/mL DMPG or 
5 mg/mL PS 80/SO (40/60) 
Additionally, it was to be investigated if the viscosity of suspensions with 5 mg/mL of the 
40/60 mixture depends on the pH as seen for DMPG containing samples. In contrast to DMPG, 
PS 80 and SO are nonionic molecules and thus, potentially less sensitive to changes in pH 
value. Nevertheless, the interaction with the net uncharged API molecule in solution and API 
particle surface might be stronger at pH 5.5 leading to a lower viscosity. Figure 77 A shows 
the viscosity of all suspensions dependent on pH at ẙ = 0.2 1/s. The viscosity of PS 80/SO 
containing samples is not affected by pH. In contrast to the DMPG containing suspensions the 
formulations with the surfactant mixture are physical stable, flocculated systems within the 
investigated pH range, making the suspensions more robust to pH variation. Nevertheless, all 
PS 80/SO or DMPG containing suspensions have a lower viscosity than the WfI suspension 
at the physiologically relevant pH value (pH 7). At a medium shear rate the viscosity of the 
surfactant mix containing suspensions tends to be even lower (at pH 6.5 and 7) than that of 
the DMPG containing suspensions (Figure 77 B). The viscosity of suspensions with the 
surfactant mixtures is also lower than that of the other systems at the highest shear rate 
(ẙ = 1000 1/s) for pH 6 – 7 (Figure 77 C). 
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Figure 77 A: Viscosity of 300 mg/mL API suspensions in WfI, with 2 mg/mL DMPG, 2 mg/mL DMPG and 
150 mM NaCl or 5 mg/mL PS 80/SO (40/60) as a function of pH at ẙ = 0.2 1/s. Error bars represent standard 
deviation from triplicate measurements. 
 
 
Figure 77 B: Viscosity of 300 mg/mL API suspensions in WfI, with 2 mg/mL DMPG, 2 mg/mL DMPG and 
150 mM NaCl or 5 mg/mL PS 80/SO (40/60) as a function of pH at ẙ = 12.6 1/s. Error bars represent standard 
deviation from triplicate measurements. 
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Figure 77 C: Viscosity of 300 mg/mL API suspensions in WfI, with 2 mg/mL DMPG, 2 mg/mL DMPG and 
150 mM NaCl or 5 mg/mL PS 80/SO (40/60) as a function of pH at ẙ = 1000 1/s. Error bars represent standard 
deviation from triplicate measurements. 
 
In conclusion, the viscosity of 300 mg/mL Cilengitide suspension could be reduced by the 
addition of surfactants. The addition of PS 80 only does not lower sufficiently the viscosity in 
the low shear range. At low and medium shear rates the viscosity of the suspensions does not 
show any dependency on HLB or surfactant concentration except for 7.5 or 10 mg/mL of 
PS 80/SO 40/60 and 30/70. These suspensions are more viscous possibly due to the higher 
viscosity of the surfactant dispersion itself. At the highest shear rate, suspensions with 5 mg/mL 
PS 80/SO 40/60 exhibit the lowest viscosity. For suspensions with 5 mg/mL PS 80/SO 40/60 
no dependency on pH is seen for suspensions containing a surfactant mix. Furthermore, 
suspensions with 5 mg/mL PS 80/SO 40/60 tend to be less viscous at pH 6.5 and 7 than DMPG 
containing suspensions at ẙ = 12.6 1/s. Thus, the PS 80/SO formulations are robust systems 
and a suitable alternative to the use of phospholipids. 
 
 
6.2 Physical stability during storage of suspensions containing 300 mg/mL 
Cilengitide and 2 mg/mL DMPG or 5 mg/mL PS 80/SO (40/60) 
For a suspension with 2 mg/mL DMPG and 5 mg/mL PS 80/SO 40/60, 150 mM NaCl and 
300 mM glucose the physical stability over one year storage at 2 – 8 °C was tested. All the 
suspension had an initial pH of 7. 
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6.2.1 Initial characteristics 
The initial particle size distribution of the different formulations is shown in Figure 78. The 
smallest particles (D(0.05) and D(0.10)) are comparable in size for all suspensions. The 
surfactant mix containing formulations exhibit lower (D(0.50), D(0.90) and D(0.95) values than 
the DMPG containing samples possibly indicating reduced particle interaction resulting in less 
or smaller agglomerates. This may correspond to lower viscosity values for the PS 80/SO 
containing suspensions at high shear rates (Figure 77 C). However, the microscopic pictures 
show comparable structures for the PS80/SO and phospholipid suspensions (Figure 79). The 
addition of NaCl or glucose does not affect the particle size of the suspensions. 
 
 
Figure 78: Particle size distribution of suspensions containing 300 mg/mL API in WfI, with 2 mg/mL DMPG 
or 5 mg/mL PS 80/SO (40/60) and 150 mM NaCl or 300 mM glucose after production. 
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Figure 79: Microscopic pictures of suspensions with 300 mg/mL API and 2 mg/mL DMPG (A) and 
150 mM NaCl (C) or 300 mM glucose (E) or 5 mg/mL PS 80/SO (40/60) (B) and 150 mM NaCl (D) or 300 mM 
glucose (F) diluted 1:10. Bar corresponds to 200 µm. 
 
 
6.2.2 Particle size stability 
Table 11 shows the result of the particle size stability. For a better overview only the values for 
D(0.05), D(0.50) and D(0.95) at the beginning and the end of storage are presented. All the 
suspensions show acceptable particle size stability for one year at 2 – 8 °C as particle size 
remains in the acceptable range. 
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Formulation D(0.05) [µm] D(0.50) [µm] D(0.95) [µm] 
WfI 
start 1.22 10.03 35.42 
52 weeks 1.39 13.31 44.79 
 
Relative increase 
[%] 
13.9 32.7 26.5 
2 mg/mL DMPG 
start 1.18 10.69 39.50 
52 weeks 1.37 13.99 43.88 
 
Relative increase 
[%] 
16.1 30.9 11.1 
2 mg/mL DMPG, 
9 mg/mL NaCl 
start 1.25 11.65 35.44 
52 weeks 1.42 14.54 41.95 
Relative increase 
[%] 13.6 24.8 18.4 
2 mg/mL DMPG, 
50 mg/mL glucose 
start 1.25 11.78 37.55 
52 weeks 1.54 13.78 42.69 
Relative increase 
[%] 23.2 17.0 13.7 
5 mg/mL PS 80/SO 
(40/60) 
start 1.11 6.96 27.09 
52 weeks 1.14 8.70 31.71 
Relative increase 
[%] 2.7 25.0 17.1 
5 mg/mL PS 80/SO 
(40/60), 
9 mg/mL NaCl 
start 1.16 8.11 35.08 
52 weeks 1.17 9.34 38.52 
Relative increase 
[%] 0.9 15.2 9.8 
5 mg/mL PS 80/SO 
(40/60), 
50 mg/mL glucose 
start 1.15 7.37 27.60 
52 weeks 1.15 8.74 30.84 
Relative increase 
[%] 0 18.6 11.7 
Table 11: Particle size stability of suspensions with 300 mg/mL API and 2 mg/mL DMPG or 5 mg/mL PS 
80/SO (40/60) and 150 mM NaCl or 300 mM glucose stored at 2-8 °C for one year. 
 
For comparison, a formulation containing 2 mg/mL of the more hydrophilic phospholipid DSPE-
PEG 2000 was evaluated. This formulation showed a more pronounced particle size increase 
as compared to the tested formulations (Table 12). The observed particle size increase 
correlates with solubility changes during storage. The solubility increases to 8.4 ± 0.4 mg/mL 
within 48 h and decreases again to 6.1 ± 0.2 mg/mL after 10 days. In contrast, the solubility 
for Cilengitide in WfI or 2 mg/mL DMPG remains at 5 or 6 mg/mL during storage. 
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Formulation D(0.05) [µm] D(0.50) [µm] D(0.95) [µm] 
2 mg/mL DSPE-
PEG 2000 
start 1.28 11.94 37.09 
52 weeks 2.53 18.57 52.59 
Relative increase 
[%] 50.6 64.3 70.5 
Table 12: Particle size stability of suspensions with 300 mg/mL API and 2 mg/mL DSPE-PEG 2000 stored at 
2 – 8 °C for one year. 
 
 
6.2.3 Sedimentation rate of DMPG and PS 80/SO containing suspensions 
Particles suspended in water build a flocculated system and show slow sedimentation. This is 
demonstrated by measuring the transmission over time for suspensions with 150 mg/mL API 
in WfI and by determining the sedimentation degree for the highly concentrated samples 
(300 mg/mL API in WfI). For transmission measurements, the Cilengitide concentration is 
limited to 150 mg/mL, otherwise the transmitted light signal is too low. Particles suspended in 
DMPG or PS 80/SO containing formulation may sediment faster due to the reduced particle 
interaction. But the rate may also be comparable due to the high solid content which possibly 
affects the rate more than the reduced interaction. 
Suspensions with 150 mg/mL Cilengitide and the equivalent ratio of surfactant mix (2.5 mg/mL 
PS 80/SO 40/60) or DMPG (1 mg/mL) without isotonic agents show slow sedimentation with 
3.1 µm/mL for the DMPG containing suspension and 1.7 µg/mL for the suspension in WfI and 
in presence of the surfactant mix (Figure 80). Particles suspended in DMPG containing 
medium might sediment faster as they are more separated and thus, interact less with each 
other. 
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Figure 80: Transmission profile dependent on time and sample height and the calculated sedimentation 
rate of suspensions containing 150 mg/mL API in WfI (above), with 1 mg/mL DMPG (middle) or 2.5 mg/mL 
PS 80/SO (40/60) (below). 
 
The sedimentation degree after one year of storage is shown in Figure 81. The PS 80/SO 
containing samples have a similar sedimentation degree as the suspension in WfI (F = 0.86). 
The samples with NaCl or glucose added are comparable. Without isotonicity agent F is slightly 
higher. Suspensions with DMPG show a much smaller sediment volume. It appears that the 
addition of DMPG disrupts the scaffold-like structure which is based on electrostatic repulsion 
of the particles. The separated particles build a more compact sediment. In contrast, the 
strongly interacting structure remains in presence of the PS 80/SO mix. 
 
 
Figure 81: Sedimentation degree calculated for suspensions with 300 mg/mL API stored for one year 
(2 - 8 °C). Error bars represent standard deviation from triplicate measurements. 
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In general, the sedimentation rate of all tested formulations is low enough to allow for sufficient 
time to withdraw the homogenized suspension in reproducible doses from the vial. The overall 
high sedimentation degree suggests a good stability with respect to caking. 
 
 
6.2.4 Resuspendability 
According to the Ph. Eur. suspensions should be resuspendable with gentle shaking. 
Consequently, the time required for the resuspension of the formulations is determined as a 
function of storage time (Figure 82). Advantageous performance of the PS 80/SO samples is 
expected due to the less compressed sediment. Beads can be used to facilitate the 
resuspension [98]. Three metal beads made of stainless steel with a 1 mm diameter were 
added in some samples as indicated. 
 
Figure 82: Time required for resuspension of formulations containing 300 mg/mL API, 2 mg/mL DMPG or 
5 mg/mL PS 80/SO (40/60) and 150 mM NaCl or 300 mM glucose stored for one year at 2 – 8 °C with (+) or 
without (-) beads. Error bars represent standard deviation from triplicate measurements. 
 
The suspensions in WfI and with 2 mg/mL DMPG require comparable time for resuspension. 
The maximum time is about 25 min for the DMPG suspension with NaCl after 26 weeks of 
storage (without beads). For DMPG containing samples without isotonic agent beads generally 
reduce the time (except for the sample stored for 52 weeks) while the beads have no clear 
beneficial effect on the suspensions in WfI and the DMPG formulations with NaCl or glucose. 
The NaCl containing samples tend to be more difficult to resuspend compared to the other 
DMPG formulations. Thus, the DMPG samples can be resuspended after storage up to 1 year, 
but the time required for resuspension becomes too long to be acceptable. In contrast, the 
0
5
10
15
20
25
30
35
 -  +  -  +  -  +  -  +  -  +  -  +  -  +
WfI DMPG DMPG,
NaCl
DMPG,
glucose
PS 80/SO
(40/60)
PS 80/SO
(40/60),
NaCl
PS 80/SO
(40/60),
glucose
T
im
e
 [
m
in
]
1 w 2 w 4 w 8 w 12 w 26 w 52 w
Formulation development for 300 mg/mL Cilengitide suspensions 
97 
PS 80/SO containing samples are easily resuspendable in less than 3.2 ± 0.7 min up to one 
year and show lower variability as compared to the WfI and DMPG containing samples. The 
PS 80/SO 40/60 containing suspensions without isotonicity agent or with glucose added 
require less time to be resupended as compared to NaCl containing samples, particularly with 
beads added. The glucose containing sample stored for one week and with beads added 
requires the minimum time for resuspension with only 0.2 ± 0.05 min. This advantage of the 
PS 80/SO systems is in line with the expectations due to the less compressed sediment after 
storage and the lower viscosities at the higher shear rates. 
 
 
6.2.5 Syringeability 
The syringeability during storage is compared by measuring the required time to draw out 1 mL 
of the formulation using a 25 Gauge needle (Figure 83). Contrary to the WfI suspensions, all 
analyzed formulations can be drawn out of the vial except for the DMPG containing suspension 
with NaCl and stored for 26 weeks. In this case, persistent agglomerates are observed which 
cannot be disintegrated by vigorous shaking (Figure 84). The DMPG containing suspensions 
require significantly more time to be withdrawn as compared to the PS80/SO samples. In some 
cases air bubbles have to be removed leading to the higher times for the DMPG samples. The 
addition of isotonicity agents does not influence the syringeability. Soft agglomerates are 
observed in case of samples containing DMPG and NaCl stored for 4 weeks, DMPG and 
glucose stored for 12 weeks and PS 80/SO and NaCl stored for 8 weeks. The soft 
agglomerates can be destroyed by manual, vigorous shaking contrary to the persistent 
agglomerates. 
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Figure 83: Time required for drawing out 1 mL of the vial for formulations containing 300 mg/mL API and 
2 mg/mL DMPG or 5 mg/mL PS 80/SO (40/60) and 150 mM NaCl or 300 mM glucose stored for one year at 
2 – 8 °C. Error bars represent standard deviation from triplicate measurements. 
 
 
Figure 84: Agglomerates observed for the formulation containing 2 mg/mL DMPG and 150 mM NaCl after 
4 weeks storage. 
 
 
6.2.6 Injectability 
Furthermore, the required force to eject the redispersed suspension from the syringe with a 
25 Gauge needle and with 10 mm/s is measured with the Texture analyzer as a function of 
formulation and storage time (Figure 85). Even the highly viscous aqueous suspension is 
injectable as discussed before. All formulations are comparable and can be ejected with less 
than 5 N during the whole storage period. 
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Figure 85: Injection force required for suspensions containing 300 mg/mL API, 2 mg/mL DMPG or 5 mg/mL 
PS 80/SO (40/60) and 150 mM NaCl or 300 mM glucose over one year using a 25 Gauge needle, a volume of 
1 mL and a speed of 10 mm/s. Error bars represent standard deviation from triplicate measurements. 
 
Overall, all the formulations show an acceptable particle size stability during the storage period 
of one year at 2 – 8 °C. The sedimentation rate is generally low enough to allow for sufficient 
time to withdraw the homogenized suspension in reproducible doses. The particles of the 
DMPG containing samples sediment faster as compared to the WfI and PS 80/SO formulations 
and interact less with each other building a compact sediment which is hard to resuspend. The 
PS 80/SO containing suspensions exhibit a loose sediment which is rapidly resuspendable. 
Furthermore, the surfactant mix containing formulations exhibit a significantly faster and easier 
syringeability compared to the phospholipid containing systems. Persistent agglomerates are 
seen for the formulation with DMPG and NaCl stored for 26 weeks prohibiting the withdrawal. 
Soft agglomerates are seen for suspensions with DMPG and NaCl after 4 weeks storage, 
DMPG and glucose after 12 weeks storage and also for PS 80/SO containing formulations with 
NaCl after 8 weeks storage. Finally, the required force of all suspensions is low and constant 
during storage as seen for the WfI formulations. 
 
 
6.3 Conclusion 
The viscosity of the highly viscous formulation containing 300 mg/mL Cilengitide is successfully 
reduced by the addition of surfactants. However, the variation of pH or the addition of ions 
does not significantly influence the viscosity. An increase of particle size offering a lower 
viscosity is not suitable for a formulation applicated via a 25 Gauge needle.  
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Suspensions containing DMPG or other phospholipids show a significant lower viscosity 
around the isoelectric point at pH 5.5. The interaction between the phospholipid and the particle 
surface is strongest leading to a densely covered particle surface. The particles are separated 
due to weakened interparticle forces and introduction of repulsive forces resulting in a 
deflocculated system which is physically unstable. At pH 7, the viscosity is sufficiently low and 
no caking is observed. These formulations with additionally NaCl or glucose are used for final 
evaluation of the stability. In contrast, suspensions with PS 80/SO mixtures are stable, 
flocculated systems over the whole pH range and viscosity is independent on pH. Mixture ratio 
and concentration do not significantly affect the viscosity in the low shear range. It is found that 
pure PS 80 does not sufficiently lower the viscosity. At high shear rates, suspensions with 
5 mg/mL PS 80/SO (40/60) show lowest viscosity. They are finally used for stability evaluation 
in combination with NaCl or glucose. 
The evaluation of the storage stability shows an acceptable particle size stability for all 
formulations during storage at 2 - 8 °C over one year. The sedimentation rate of the 
suspensions with DMPG or PS 80/SO is very low ensuring an adequate dosing. The 
sedimentation degree of DMPG containing systems is lower than the PS 80/SO systems 
indicating a more compressed sediment. This is in line with the higher times needed for 
resuspension of these formulations. With respect to syringeability suspensions with PS 80/SO 
require less time to be drawn out of the vial compared to DMPG containing formulations. 
However, agglomerates are observed during storage for all DMPG containing formulations and 
for formulations with PS 80/SO combined with NaCl which comprise the syringeability. Even 
though soft agglomerates can be destroyed by vigorous shaking these suspensions are not 
suitable as final formulation. The injectability of all formulations via a 25 Gauge needle is 
feasible. Finally, a formulation with PS 80/SO (40/60) with glucose is recommended. 
Considering the interaction mechanism for DMPG and Cilengitide it is found that DMPG 
bicelles built in water are destroyed when dissolved Cilengitide is added. The formation of 
smaller, spherical micelles is seen in Cryo-TEM pictures and is connected with a turbidity 
reduction. Thus, the theory for DMPG acting as a ball bearing is not confirmed. Hydrophobic 
interactions between the myristoyl chain of DMPG and the phenylalanine and valine moieties 
of Cilengitide are observed at all pH values. Furthermore, it is expected that electrostatic 
interaction takes place between the negatively charged phosphate group and the positively 
charged arginine of Cilengitide. The hydrophobic interaction is most pronounced at the 
isoelectric point of Cilengitide leading to a densely covered particle surface. This is confirmed 
by a Zeta potential maximum of the suspended particles at pH 5 – 6. The particles are 
separated due to reduced interparticle forces and introduced repulsive forces. Finally, a 
deflocculated, instable system is formed which is not suitable as final formulation. However, 
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DMPG partly interacts with the Cilengitide particle surface at pH 7 reducing the viscosity by 
lowering the interparticle forces. The surface is only partly covered confirmed by a slight 
increase of the Zeta potential. A flocculated state exist which does not show caking. 
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7 Final summary of the thesis 
The aim of the thesis was to develop a highly concentrated, physically stable suspension of 
Cilengitide for subcutaneous application with a target concentration of 300 mg/mL API. The 
anhydrous polymorph A1 is the most stable polymorph without any tendency for conversion 
into another polymorphic form and thus, suitable for the development of a subcutaneous 
suspension. The molecule has an acidic carboxyl group of aspartic acid and a basic 
guanidinium group of arginine leading to a detected isoelectric point of 5.5. The surface of a 
Cilengitide A1 molecule is hydrophobic due to the outwardly orientated amino acids 
phenylalanine and valine. The non-micronized raw material contained needle- and rod-shaped 
particles with a size of approximately 570 µm and showed good flowability in contrast to 
micronized material containing particles of approximately 30 µm. However, the non-micronized 
material would not have been applicable via a 25 Gauge needle due to the large particles. 
Consequently, the influence of stirring on particle size and structure of non-micronized material 
suspended in water was evaluated to possibly find a comminuting method ensuring a suitable 
particle size distribution with a maximum of 100 µm. 
Cilengitide particles built a continuous, scaffold-like structure when suspended in water and 
homogenized. Particle sizes comparable to micronized material resulted after stirring of non-
micronized material. Particles broke at predetermined breaking points leading to similar 
particle sizes. Since long stirring times were required and difficulties in upscaling were 
expected the use of non-micronized material was not recommended despite the advantage of 
very good flow properties. Micronized particles are rather stable against comminuting methods 
with higher energy levels like ultrasound, Ultraturrax® and ball mill treatment. The API 
concentration and the addition of metal beads to possibly facilitate resuspension also did not 
affect the particle size distribution. 
The physical stability of suspensions was evaluated including particle size, sedimentation 
behavior, resuspendability, viscosity, syringeability and injectability. An acceptable particle 
size stability was seen upon storage at 2-8 °C, 25 °C / 60 % r.H. and 45 °C / 75 % r.H. The 
particles settled as flocs building a loose sediment. The sedimentation rate decreased with 
increasing API concentration due to spatial hindrance. For the samples with 300 mg/mL API a 
very slow sedimentation rate was found easily enabling an adequate dosing and application. 
The highly concentrated suspensions could be resuspended within short times due to the 
loosely packed sediment. Overall, the physical stability of 300 mg/mL Cilengitide suspended 
in WfI was acceptable. However, suspensions containing the target concentration of 
300 mg/mL API were too viscous to be withdrawn out of the vial. The rheological 
characterization of differently concentrated suspensions was performed with special attention 
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to shear rates of ẙ = 0.2 1/s and ẙ =12.6 1/s characterizing the withdrawal from the vial 
(syringeability) and ẙ = 1000 1/s to reflect the injection of the suspension with a 25 Gauge 
needle. It was seen that the viscosity significantly increased with increasing concentration 
mainly in the low shear range compromising the syringeability of the highly concentrated 
suspensions. All the samples showed a marked shear-thinning behavior resulting in low 
viscosity at high shear rates. Thus, the injection of even 300 mg/mL suspensions with a 
25 Gauge needle was feasible and confirmed by ejection force measurements. Consequently, 
a viscosity reduction of the highly concentrated suspension was essential to ensure the 
syringeability. 
Several strategies for viscosity reduction were evaluated. The variation of the pH and the 
addition of ions did not affect the viscosity substantially. A decrease in viscosity by use of larger 
particles was not suitable. Utilizing “non-micronized” material, despite a D(0.95) value of about 
40 µm, needle shaped particles longer than 120 µm were detected. These particles blocked 
the 25 Gauge needle and such larger particles would need to be completely rouled out. Finally, 
the addition of surfactants successfully lowered the viscosity of the highly concentrated 
suspension. Phospholipids, mainly dimyristoylphosphoglycerol (DMPG), decreased the 
viscosity by introducing electrosteric repulsive forces and by reducing particle interaction. The 
viscosity reduction was most pronounced at pH 5.5 where hydrophobic interaction was 
strongest and the surface of Cilengitide particles was densely covered with DMPG molecules 
resulting in particle separation. Despite of this, these formulations were physically unstable as 
caking was observed and thus, not suitable as final formulation. The theory for DMPG acting 
as a ball bearing reducing the interparticle interaction could not be confirmed. Spherical DMPG 
bicelles were destroyed when adding Cilengitide and spherical micelles formed. Varying the 
hydrophobic chain length of the phospholipid did not show any effect. Mixtures of the 
commonly used non-ionic surfactants polysorbate 80 (PS 80) and sorbitan monooleate (SO) 
lowered the viscosity comparable to the phospholipids. The viscosity reduction generally did 
not depend on mixing ratio and concentration. In contrast to the phospholipid containing 
formulations, the pH did not affect the viscosity and thus, the PS 80/SO containing formulations 
were more robust. 
For the final evaluation of the physical stability and performance, suspensions with 2 mg/mL 
DMPG or 5 mg/mL PS 80/SO (40/60) and 150 mM NaCl or 300 mM glucose at pH 7 were 
used. All systems showed a comparable initial particle size and acceptable particle size 
stability. The sedimentation rate was generally low ensuring adequate dosing. Samples with 
PS 80/SO showed more loosely packed sediments compared to the DMPG containing 
formulations. Consequently, the PS 80/SO formulations could be resuspended considerably 
faster. During storage for DMPG containing formulations with NaCl or glucose and PS 80/SO 
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in combination with NaCl particle agglomerates were formed compromising the syringeability 
due to needle clogging. The time needed to draw 1 mL out of the vial was less for PS 80/SO 
systems than for suspensions with DMPG. The injectability was given for all formulations. 
Summarizing, a physically stable, highly concentrated suspension for subcutaneous 
application by adding 5 mg/mL PS80/SO (40/60) in combination with glucose was achieved. 
The viscosity was efficiently reduced by the addition of either a phospholipid or a mixture 
containing PS 80 and SO. However, the PS80/SO containing systems combined with glucose 
showed superior storage stability with respect to resuspendability and syringeability. 
Consequently, they are recommended as suitable final formulations. In future studies, the 
effect of surfactant and viscosity on the API pharmacokinetics needs to be studied. 
Furthermore, a more general evaluation of the concept of surfactant based viscosity reduction 
of aqueous API suspensions would be interesting.  
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